A Phase 3 interventional study of ATM-AVI and MTZ in Complicated Intra-abdominal Infection, Hosptial Acquired Pneumonia and Ventilator Associated Pneumonia, sponsored by Pfizer. Completed at 157 sites in 21 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-10.
Sponsored by Pfizer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies in Pneumonia, Ventilator-Associated with a site in China — 10 open to participants now, 11 under way, none of them phase 3. Pneumonia, Ventilator-Associated · China.
Among the 26 studies in Pneumonia, Ventilator-Associated with a site in China, this one is the 5th largest by enrollment of the 17 interventional ones that give a count, is one of 2 that started in 2018, is one of 3 in phase 3, and was the 7th registered.
420 studies on the registry are indexed under Pneumonia, Ventilator-Associated; 83 are open to participants now.
Browse Pneumonia, Ventilator-Associated studies →10 of the 26 studies in Pneumonia, Ventilator-Associated with a site in China are open now. Recruiting first, the newest first:
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Sites in China
Ages 18+
Sir Run Run Shaw Hospital · Sites in China
Ages 18+
Affiliated Hospital of Nantong University · Sites in China
Ages 18–90
Qilu Hospital of Shandong University · Sites in China
Ages 18+
Southeast University, China · Sites in China
Ages 18–80
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 47 Pneumonia, Ventilator-Associated studies recruiting now, 36 (77%) set no upper age limit and 6 (13%) stop at 75 or younger; 6 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 5 · Phase 3 4 · Phase 4 2
First in 2009; this study’s year is marked. 2 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 422 is above the median of 115 across 276 interventional studies indexed under Pneumonia, Ventilator-Associated.
Median enrollment 174 across the 17 interventional studies, 200 across the 9 observational. Of the 10 that completed or were terminated, 4 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 26 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 148 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Pfizer has 9 studies filed under Pneumonia, Ventilator-Associated — fewer than ten, so there is no comparison to draw.
3 of the studies in Pneumonia, Ventilator-Associated with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06819462Southeast University, ChinaInhaled Colistin to Prevent Ventilator-Associated Pneumonia in Patients With Acute Brain Injury | 2026-12-31 |
| NCT07512596Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Study on the Safety and Efficacy of Polymyxin E2 Methanesulfonate for Injection in the Treatment of Hospital-Acquired Bacterial Pneumonia/Ventilator-Associated Bacterial Pneumonia Caused by Carbapenem-Resistant Gram-Negative Bacteria | 2027-07 |
| NCT07268560Sir Run Run Shaw HospitalReal-World Effectiveness of Aztreonam-Avibactam Against MBL-Producing CRE | 2027-07-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 26 studies in Pneumonia, Ventilator-Associated with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A Phase 3 comparative study to determine the efficacy, safety and tolerability of Aztreonam-Avibactam (ATM-AVI) ± Metronidazole (MTZ) versus Meropenem (MER) ± Colistin (COL) for the treatment of serious infections due to Gram negative bacteria.
A Phase 3 Prospective, Randomized, Multicenter, Open Label, Central Assessor Blinded, Parallel Group, Comparative Study To Determine The Efficacy, Safety And Tolerability Of Aztreonam-Avibactam (ATM-AVI) ± Metronidazole (MTZ) Versus Meropenem±Colistin (MER±COL) For The Treatment Of Serious Infections Due To Gram Negative Bacteria, Including Metallo Β Lactamase (MBL) - Producing Multidrug Resistant Pathogens, For Which There Are Limited Or No Treatment Options
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
All subjects:
Additional for cIAI:
Diagnosis of cIAI, EITHER:
Intra-operative/postoperative enrolment with visual confirmation of cIAI. OR Preoperative enrollment with evidence of systemic inflammatory response, physical and radiological findings consistent with cIAI; confirmation of cIAI at time of surgery within 24 hours of study entry
Additional for HAP/VAP:
Exclusion criteria:
All subjects:
Additional for cIAI
Additional for HAP/VAP
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All patients randomised to this arm will receive ATM-AVI; all patients with cIAI will receive MTZ for anaerobic cover
Drug: ATM-AVI · Drug: MTZ
All patients randomised to this arm will receive MER; addition of COL will be at investigator's discretion in line with local practice
Drug: MER · Drug: COL
(Creatinine clearance \> 50 mL/min) 6500 mg ATM/2167 mg (loading dose, extended loading dose and maintenance dose) by iv infusion on Day 1 followed by a total daily dose of 6000 mg ATM/2000 mg AVI (Creatinine clearance 31 - 50 mL/min) 4250 mg ATM/1417 mg AVI on Day 1 (loading dose, extended loading dose, maintenance dose) followed by total daily dose 3000 mg ATM/1000 mg AVI (Creatinine clearance 16 - 30 mL/min) 2700 mg ATM/900 mg AVI on Day 1 (loading dose, extended loading dose maintenance dose), followed by total daily dose 2025 mg ATM/675 mg AVI
For cIAI only; 500 mg/100 mL metronidazole iv infusion over 1hr q8h
Where pathogen initially not suspected of being MER-resistant: (Creatinine clearance \> 50 mL/min) 1000 mg meropenem by 30 min iv infusion q8h (Creatinine clearance 26 - 50 mL/min) 1000mg meropenem by 30 min iv infusion q12h (Creatinine clearance 16 - 25 mL/min) 500 mg meropenem by 30 min iv infusion q12h Where pathogen initially suspected of being MER-resistant (Creatinine clearance \> 50 mL/min) 2000 mg meropenem by 180 min iv infusion q8h (Creatinine clearance 26 - 50 mL/min) 2000 mg meropenem by 180 min iv infusion q12h (Creatinine clearance 16 - 25 mL/min) 1000 mg meropenem by 180 min iv infusion q12h
Loading dose 9 million IU by 30 -60 min iv infusion (6 million IU where weight \< 60 kg) followed by one of the following maintenance doses: (Creatinine clearance \> 50 mL/min) after a 12h interval, commence maintenance dosing 9 million IU daily in 2 or 3 divided doses by 30 -60 min iv infusions. (Creatinine clearance 31 - 50 mL/min) After a 24 hr interval, commence maintenance dosing of 6 million IU daily in 2 divided doses by 30 -60 min iv infusion (Creatinine clearance 21 - 30 mL/min) After a 24 hr interval, commence maintenance dosing 5 million IU daily in 2 divided doses by 30 -60 min iv infusion (Creatinine clearance 16 - 20 mL/min) after a 24 hr interval, commence maintenance dosing 4 million IU daily in 2 divided doses by 30 -60 min iv infusion
Percentage of Participants With Clinical Cure at Test of Cure (TOC) Visit: Intent-To-Treat (ITT) Analysis Set
Clinical cure was defined as improvement in baseline signs and symptoms such that after study treatment, no further antimicrobial treatment for the index infection (i.e., cIAI or HAP/VAP) was required. Additionally, for cIAI participants, no unplanned drainage or surgical intervention was necessary since the initial procedure. Clinical cure was determined by the Independent Clinical Adjudication Committee. 95% confidence interval (CI) was based on Jeffrey's method.
Time frame: At TOC visit (Day 28)
Percentage of Participants With Clinical Cure at TOC Visit: Clinically Evaluable (CE) Analysis Set
Clinical cure = improvement in baseline signs and symptoms such that after study treatment, no further antimicrobial treatment for the index infection (i.e., cIAI or HAP/VAP) was required. Additionally for cIAI participants, no unplanned drainage or surgical intervention was necessary since the initial procedure. Clinical cure was determined by Independent Clinical Adjudication Committee. 95% CI was based on Jeffrey's method. CE analysis set:all participants in ITT analysis set; met criteria for cIAI, or HAP/VAP; received at least 48 hours of study treatment or \<48 hours of treatment before discontinuing study drug due to AE; no concomitant antibiotics for any baseline pathogens between first dose and TOC (except protocol-allowed antibiotics); no prior antibiotics other than allowed per protocol; no important protocol deviations; no clinical outcome of indeterminate at TOC; no monomicrobial infections due to non-eligible pathogens and did not have only Gram-positive pathogens.
Time frame: At TOC visit (Day 28)
Percentage of Participants With Clinical Cure at TOC Visit: Microbiological Intent-To-Treat (Micro-ITT) Analysis Set
Clinical cure was defined as improvement in baseline signs and symptoms such that after study treatment, no further antimicrobial treatment for the index infection (i.e., cIAI or HAP/VAP) was required. Additionally, for cIAI participants, no unplanned drainage or surgical intervention was necessary since the initial procedure. Clinical cure was determined by the Independent Clinical Adjudication Committee. 95% CI was based on Jeffrey's method.
Time frame: At TOC visit (Day 28)
Percentage of Participants With Clinical Cure at TOC Visit: Microbiologically Evaluable (ME) Analysis Set
Clinical cure was defined as improvement in baseline signs and symptoms such that after study treatment, no further antimicrobial treatment for the index infection (i.e., cIAI or HAP/VAP) was required. Additionally, for cIAI participants, no unplanned drainage or surgical intervention was necessary since the initial procedure. Clinical cure was determined by the Independent Clinical Adjudication Committee. 95% CI was based on Jeffrey's method.
Time frame: At TOC visit (Day 28)
Percentage of Participants With Clinical Cure at TOC Visit by Type of Infection: ITT Analysis Set
Clinical cure was defined as improvement in baseline signs and symptoms such that after study treatment, no further antimicrobial treatment for the index infection (i.e., cIAI or HAP/VAP) was required. Additionally, for cIAI participants, no unplanned drainage or surgical intervention was necessary since the initial procedure. Clinical cure was determined by the Independent Clinical Adjudication Committee. 95% CI was based on Jeffrey's method.
Time frame: At TOC visit (Day 28)
Percentage of Participants With Clinical Cure at TOC Visit by Type of Infection: CE Analysis Set
Clinical cure = improvement in baseline signs and symptoms such that after study treatment, no further antimicrobial treatment for the index infection (i.e., cIAI or HAP/VAP) was required. Additionally, for cIAI participants, no unplanned drainage or surgical intervention was necessary since the initial procedure. Clinical cure was determined by the Independent Clinical Adjudication Committee. 95% CI was based on Jeffrey's method. CE analysis set:all participants in ITT analysis set; met criteria for cIAI, or HAP/VAP; received at least 48 hours of study treatment or \<48 hours of treatment before discontinuing study drug due to AE; no concomitant antibiotics for any baseline pathogens between first dose and TOC (except protocol-allowed antibiotics); no prior antibiotics other than allowed per protocol; no important protocol deviations; no clinical outcome of indeterminate at TOC; no monomicrobial infections due to non-eligible pathogens and did not have only Gram-positive pathogens.
Time frame: At TOC visit (Day 28)
Percentage of Participants With Clinical Cure in Participants With Metallo-beta-lactamase (MBL) Positive Pathogen at TOC Visit: Micro-ITT Analysis Set
Clinical cure was defined as improvement in baseline signs and symptoms such that after study treatment, no further antimicrobial treatment for the index infection (i.e., cIAI or HAP/VAP) was required. Additionally, for cIAI participants, no unplanned drainage or surgical intervention was necessary since the initial procedure. Clinical cure was determined by the Independent Clinical Adjudication Committee.
Time frame: At TOC visit (Day 28)
Percentage of Participants With Clinical Cure in Participants With MBL Positive Pathogen at TOC Visit: ME Analysis Set
Clinical cure was defined as improvement in baseline signs and symptoms such that after study treatment, no further antimicrobial treatment for the index infection (i.e., cIAI or HAP/VAP) was required. For cIAI participants, no unplanned drainage or surgical intervention was necessary since the initial procedure. Clinical cure was determined by the Independent Clinical Adjudication Committee.
Time frame: At TOC visit (Day 28)
Percentage of Participants With Favorable Per-Participant Microbiological Response at TOC Visit: Micro- ITT Analysis Set
Participants were determined to have a favorable microbiological response if all baseline pathogens for that participant had a favorable outcome (eradicated or presumed eradicated). Eradication: Absence of causative pathogen from an appropriately obtained specimen at the site of infection. Presumed eradication: repeat culture of specimens were not performed/clinically indicated in a participant who had a clinical response of cure.
Time frame: At TOC visit day (28)
Percentage of Participants With Favorable Per-Participant Microbiological Response at TOC Visit: ME Analysis Set
Participants were determined to have a favorable microbiological response if all baseline pathogens for that participant had a favorable outcome (eradicated or presumed eradicated). Eradication: Absence of causative pathogen from an appropriately obtained specimen at the site of infection. Presumed eradication: repeat culture of specimens were not performed/clinically indicated in a participant who had a clinical response of cure.
Time frame: At TOC Visit (Day 28)
Percentage of Participants Who Died on or Before 28 Days After Randomization: ITT Analysis Set
Percentage of participants who died on or before 28 days after randomization is reported in this outcome measure.
Time frame: From randomization up to 28 days
Percentage of Participants Who Died on or Before 28 Days After Randomization: Micro-ITT Analysis Set
Percentage of participants who died on or before 28 days after randomization is reported in this outcome measure.
Time frame: From randomization up to 28 days
Plasma Concentration of Aztreonam
Plasma concentration for aztreonam according to renal function (augmented, normal and mild, moderate and severe is presented in this outcome measure. Augmented = Creatinine clearance (CrCL) \> 150 milliliters per minute (mL/min); Normal \& Mild = CrCL \> 50 to \<=150 mL/min; Moderate = CrCL \> 30 to ≤ 50 mL/min; Severe = CrCL \> 15 to ≤ 30 mL/min.
Time frame: Anytime between 25 to 30 minutes, 3.25 to 3.5 hours, 5.5 to 6.5 hours, 7.5 to 8.5 hours post start of infusion on Day 1; 2.75 to 3 hours, 3.5 to 4.5 hours, 5 to 6 and 7 to 8 hours post start of infusion on Day 4
Plasma Concentration of Avibactam
Plasma concentration for avibactam according to renal function (augmented, normal and mild, moderate and severe is presented in this outcome measure. Augmented = CrCL \> 150 mL/min; Normal \& Mild = CrCL \> 50 to \<=150 mL/min; Moderate = CrCL \> 30 to ≤ 50 mL/min; Severe = CrCL \> 15 to ≤ 30 mL/min.
Time frame: Anytime between 25 to 30 minutes, 3.25 to 3.5 hours, 5.5 to 6.5 hours, 7.5 to 8.5 hours post start of infusion on Day 1; 2.75 to 3 hours, 3.5 to 4.5 hours, 5 to 6 and 7 to 8 hours post start of infusion on Day 4
Maximum Plasma Concentration for a Dosing Interval at Steady-State (Cmax, ss) According to Clinical Response by Infection Type at TOC: Aztreonam
Population PK predicted maximum plasma concentration for a dosing interval at steady-state (Cmax,ss) for participants who received aztreonam-avibactam in studies C3601002 (NCT03329092) and C3601009 (NCT03580044). Clinical response categories included, clinical cure=improvement in baseline signs and symptoms such that after study treatment, no further antimicrobial treatment for the index infection (i.e., cIAI or HAP/VAP) was required. For cIAI participants, no unplanned drainage or surgical intervention was necessary since the initial procedure. Failure was defined as participants who met any of the following criteria like death (after receiving at least 48 hours of study treatment) and participants who received treatment with further antibiotics for the index infection. Indeterminate was defined as death (after receiving less than 48 hours of study treatment) and for cIAI participants inadequate infection source control at time of initial surgical procedure.
Time frame: At TOC (Day 28)
Percentage of Time That Free Plasma Concentrations Are Above the Minimum Inhibitory Concentration Over a Dosing Interval (%fT>MIC Aztreonam (ATM) of 8 mg/L) According to Clinical Response by Infection Type at TOC: Aztreonam
Population PK predicted (%fT\>MIC ATM of 8 mg/L) for participants who received aztreonam-avibactam in studies C3601002 (NCT03329092) and C3601009 (NCT03580044). Clinical response categories included, clinical cure=improvement in baseline signs and symptoms such that after study treatment, no further antimicrobial treatment for the index infection (i.e., cIAI or HAP/VAP) was required. For cIAI participants, no unplanned drainage or surgical intervention was necessary since the initial procedure. Failure was defined as participants who met any of the following criteria like death (after receiving at least 48 hours of study treatment) and participants who received treatment with further antibiotics for the index infection. Indeterminate was defined as death (after receiving less than 48 hours of study treatment) and for cIAI participants inadequate infection source control at time of initial surgical procedure.
Time frame: At TOC (Day 28)
Area Under the Plasma Concentration-time Curve Over 24 Hours at Steady-state (AUC24,ss ) According to Clinical Response by Infection Type at TOC: Aztreonam
Population PK predicted (AUC24,ss) for participants who received aztreonam-avibactam in studies C3601002 (NCT03329092) and C3601009 (NCT03580044). Clinical response categories included, clinical cure=improvement in baseline signs and symptoms such that after study treatment, no further antimicrobial treatment for the index infection (i.e., cIAI or HAP/VAP) was required. For cIAI participants, no unplanned drainage or surgical intervention was necessary since the initial procedure. Failure was defined as participants who met any of the following criteria like death (after receiving at least 48 hours of study treatment) and participants who received treatment with further antibiotics for the index infection. Indeterminate was defined as death (after receiving less than 48 hours of study treatment) and for cIAI participants inadequate infection source control at time of initial surgical procedure.
Time frame: 0 to 24 hours at TOC (Day 28)
Maximum Plasma Concentration for a Dosing Interval at Steady-state (Cmax,ss) According to Microbiological Response by Infection Type at TOC: Aztreonam
Population PK predicted (Cmax,ss) for participants who received ATM-AVI in studies C3601002 (NCT03329092) and C3601009 (NCT03580044). Microbiological response included Favorable =baseline pathogens for participant had a favorable outcome. Eradication: Absence of causative pathogen from an appropriately obtained specimen at site of infection. Presumed eradication: repeat culture of specimens were not performed/clinically indicated in a participant who had a clinical response of cure. Unfavorable=persistence, persistence with increasing MIC, or presumed persistence. Persistence= Causative organism still present from appropriately obtained specimen at site of infection. Presumed persistence= Participant assessed as a clinical failure and repeat culture of specimens were not performed/clinically indicated. Indeterminate = death (after receiving \< 48 hours of study treatment) and for cIAI participants inadequate infection source control at time of initial surgical procedure.
Time frame: At TOC (Day 28)
Area Under the Plasma Concentration-time Curve Over 24 Hours at Steady-state (AUC24,ss) According to Microbiological Response by Infection Type at TOC: Aztreonam
Population PK predicted (AUC24,ss) for participants who received ATM-AVI in studies C3601002 (NCT03329092) and C3601009 (NCT03580044). Microbiological response included Favorable =baseline pathogens for participant had a favorable outcome. Eradication: Absence of causative pathogen from an appropriately obtained specimen at site of infection. Presumed eradication: repeat culture of specimens were not performed/clinically indicated in a participant who had a clinical response of cure. Unfavorable=persistence, persistence with increasing MIC, or presumed persistence. Persistence= Causative organism still present from appropriately obtained specimen at site of infection. Presumed persistence= Participant assessed as a clinical failure and repeat culture of specimens were not performed/clinically indicated. Indeterminate = death (after receiving \< 48 hours of study treatment) and for cIAI participants inadequate infection source control at time of initial surgical procedure.
Time frame: 0 to 24 hours at TOC (Day 28)
Percentage of Time That Free Plasma Concentrations Are Above the Minimum Inhibitory Concentration Over a Dosing Interval (%fT>MIC Aztreonam (ATM) of 8 mg/L) According to Microbiological Response by Infection Type at TOC: Aztreonam
Population PK predicted (%fT\>MIC ATM of 8 mg/L) for participants who received ATM-AVI in studies C3601002 (NCT03329092) and C3601009 (NCT03580044). Microbiological response included Favorable =baseline pathogens for participant had a favorable outcome. Eradication: Absence of causative pathogen from an appropriately obtained specimen at site of infection. Presumed eradication: repeat culture of specimens were not performed/clinically indicated in a participant who had a clinical response of cure. Unfavorable=persistence, persistence with increasing MIC, or presumed persistence. Persistence= Causative organism still present from appropriately obtained specimen at site of infection. Presumed persistence= Participant assessed as a clinical failure and repeat culture of specimens were not performed/clinically indicated. Indeterminate = death (after receiving \< 48 hours of study treatment) and for cIAI participants inadequate infection source control at time of initial surgical procedure.
Time frame: At TOC (Day 28)
Area Under the Plasma Concentration-time Curve Over 24 Hours at Steady-state (AUC24,ss) According to Clinical Response by Infection Type at TOC: Avibactam
Population PK predicted (AUC24,ss) for participants who received aztreonam-avibactam in studies C3601002 (NCT03329092) and C3601009 (NCT03580044). Clinical response categories included, clinical cure=improvement in baseline signs and symptoms such that after study treatment, no further antimicrobial treatment for the index infection (i.e., cIAI or HAP/VAP) was required. For cIAI participants, no unplanned drainage or surgical intervention was necessary since the initial procedure. Failure was defined as participants who met any of the following criteria like death (after receiving at least 48 hours of study treatment) and participants who received treatment with further antibiotics for the index infection. Indeterminate was defined as death (after receiving less than 48 hours of study treatment) and for cIAI participants inadequate infection source control at time of initial surgical procedure.
Time frame: 0 to 24 hours at TOC (Day 28)
Maximum Plasma Concentration for a Dosing Interval at Steady-state (Cmax,ss ) According to Clinical Response by Infection Type at TOC: Avibactam
Population PK predicted (Cmax,ss) for participants who received aztreonam-avibactam in studies C3601002 (NCT03329092) and C3601009 (NCT03580044). Clinical response categories included, clinical cure=improvement in baseline signs and symptoms such that after study treatment, no further antimicrobial treatment for the index infection (i.e., cIAI or HAP/VAP) was required. For cIAI participants, no unplanned drainage or surgical intervention was necessary since the initial procedure. Failure was defined as participants who met any of the following criteria like death (after receiving at least 48 hours of study treatment) and participants who received treatment with further antibiotics for the index infection. Indeterminate was defined as death (after receiving less than 48 hours of study treatment) and for cIAI participants inadequate infection source control at time of initial surgical procedure.
Time frame: At TOC (Day 28)
Percent of Time That Free Plasma Concentrations Are Above the Threshold Concentration Over a Dosing Interval (%fT>CT of 2.5mg/L) According to Clinical Response by Infection Type at TOC: Avibactam
Population PK predicted (%fT\>CT of 2.5mg/L) for participants who received aztreonam-avibactam in studies C3601002 (NCT03329092) and C3601009 (NCT03580044). Clinical response categories included, clinical cure=improvement in baseline signs and symptoms such that after study treatment, no further antimicrobial treatment for the index infection (i.e., cIAI or HAP/VAP) was required. For cIAI participants, no unplanned drainage or surgical intervention was necessary since the initial procedure. Failure was defined as participants who met any of the following criteria like death (after receiving at least 48 hours of study treatment) and participants who received treatment with further antibiotics for the index infection. Indeterminate was defined as death (after receiving less than 48 hours of study treatment) and for cIAI participants inadequate infection source control at time of initial surgical procedure.
Time frame: At TOC (Day 28)
Area Under the Plasma Concentration-time Curve Over 24 Hours at Steady-state (AUC24,ss) According to Microbiological Response by Infection Type at TOC: Avibactam
Population PK predicted (AUC24,ss) for participants who received ATM-AVI in studies C3601002 (NCT03329092) and C3601009 (NCT03580044). Microbiological response included Favorable =baseline pathogens for participant had a favorable outcome. Eradication: Absence of causative pathogen from an appropriately obtained specimen at site of infection. Presumed eradication: repeat culture of specimens were not performed/clinically indicated in a participant who had a clinical response of cure. Unfavorable=persistence, persistence with increasing MIC, or presumed persistence. Persistence= Causative organism still present from appropriately obtained specimen at site of infection. Presumed persistence= Participant assessed as a clinical failure and repeat culture of specimens were not performed/clinically indicated. Indeterminate = death (after receiving\<48 hours of study treatment) and for cIAI participants inadequate infection source control at time of initial surgical procedure.
Time frame: 0 to 24 hours At TOC (Day 28)
Maximum Plasma Concentration for a Dosing Interval at Steady-state (Cmax,ss (mg/L)) According to Microbiological Response by Infection Type at TOC: Avibactam
Population PK predicted (Cmax,ss (mg/L)) for participants who received ATM-AVI in studies C3601002 (NCT03329092) and C3601009 (NCT03580044). Microbiological response included Favorable =baseline pathogens for participant had a favorable outcome. Eradication: Absence of causative pathogen from an appropriately obtained specimen at site of infection. Presumed eradication: repeat culture of specimens were not performed/clinically indicated in a participant who had a clinical response of cure. Unfavorable=persistence, persistence with increasing MIC, or presumed persistence. Persistence= Causative organism still present from appropriately obtained specimen at site of infection. Presumed persistence= Participant assessed as a clinical failure and repeat culture of specimens were not performed/clinically indicated. Indeterminate = death (after receiving\<48 hours of study treatment) and for cIAI participants inadequate infection source control at time of initial surgical procedure.
Time frame: At TOC (Day 28)
Percent of Time That Free Plasma Concentrations Are Above the Threshold Concentration Over a Dosing Interval; (%fT>CT of 2.5 mg/L) According to Microbiological Response by Infection Type at TOC: Avibactam
Population PK predicted (%fT\>CT of 2.5 mg/L) for participants who received ATM-AVI in studies C3601002 (NCT03329092) and C3601009 (NCT03580044). Microbiological response included Favorable =baseline pathogens for participant had a favorable outcome. Eradication: Absence of causative pathogen from an appropriately obtained specimen at site of infection. Presumed eradication: repeat culture of specimens were not performed/clinically indicated in a participant who had a clinical response of cure. Unfavorable=persistence, persistence with increasing MIC, or presumed persistence. Persistence= Causative organism still present from appropriately obtained specimen at site of infection. Presumed persistence= Participant assessed as a clinical failure and repeat culture of specimens were not performed/clinically indicated. Indeterminate = death (after receiving \< 48 hours of study treatment) and for cIAI participants inadequate infection source control at time of initial surgical procedure.
Time frame: At TOC (Day 28)
Number of Participants With Adverse Events (AEs) and Serious AEs
An adverse event (AE) was any untoward medical occurrence in a study participant administered medicinal product,; the event need not necessarily have a causal relationship with product treatment or usage. A serious adverse event (SAE) was any untoward medical occurrence at any dose that: resulted in death; was life-threatening; required inpatient hospitalization or prolongation of hospitalization; resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions); resulted in congenital abnormal/birth defect or considered an important medical event.
Time frame: From start of study treatment until end of late follow-up (Up to Day 45)
Number of Participants With Potentially Clinically Significant Hematology Abnormalities
Criteria for potential clinically significant hematology results were as follows: hemoglobin, hematocrit and erythrocyte \<0.7\*lower limit of normal \[LLN\] and \>30% decrease from Baseline (DFB); \>1.3\*upper limit of normal (ULN) and \>30% increase from Baseline (IFB). Platelet count \<0.65\*LLN and \> 50% decrease from baseline; \> 1.5 \* ULN and \> 100% increase from baseline. leukocyte: \< 0.65\* LLN and \> 60% decrease from baseline; \> 1.5\* ULN and 100% increase from baseline. Neutrophils/leukocytes \< 0.65 \* LLN and \>75% decrease from baseline; \> 1.6\*ULN and \> 100% increase from baseline. Lymphocytes/leukocytes \< 0.25\* LLN and \> 75% decrease from baseline;\> 1.5\* ULN and \> 100% increase from baseline, Eosinophils/leukocytes, Monocytes/leukocytes, Basophils/leukocytes \> 4.0\* ULN and \> 300% increase from baseline.
Time frame: From start of study treatment until TOC visit (Up to Day 28)
Number of Participants With Potentially Clinically Significant Clinical Chemistry Abnormalities
Albumin \< 0.5\* LLN and\> 50% decrease from baseline (DFB);\> 1.5 \* ULN and\> 50% increase from baseline (IFB). Alkaline phosphatase \< 0.5 \* LLN and\> 80% DFB;\> 3.0 \* ULN and\> 100%. Alanine and Aspartate aminotransferase \> 3.0 \* ULN and\> 100% IFB. Bicarbonate \< 0.7 \* LLN and \> 40% DFB;\> 1.3 \* ULN and\> 40% IFB. Blood urea nitrogen \< 0.2 \* LLN and \> 100% DFB; \> 3.0 \* ULN and \> 200% IFB. Calcium \< 0.7 \* LLN and \> 30% DFB;\> 1.3 \* ULN and\> 30% IFB. Chloride \< 0.8 \* LLN \>and 20% DFB; \> 1.2 \* ULN and \> 20% IFB. Creatinine \> 2.0 \* ULN and\> 100% IFB; Glucose \< 0.6 \* LLN and\> 40% DFB; \> 3.0 \* ULN and\> 200% IFB. Potassium \< 0.8 \* LLN and \> 20% DFB; \> 1.2 \* ULN and\> 20% IFB. Sodium \< 0.85 \* LLN and\> 10% DFB;\> 1.1 \* ULN and \>10% IFB. Bilirubin \> 1.5 \* ULN and \> 100% IFB.; Direct bilirubin \> 2.0 \* ULN and \> 150% IFB.
Time frame: From start of study treatment until At TOC visit (Up to Day 28)
Number of Participants With Abnormalities in Vital Signs
Vitals signs, included blood pressure and, heart rate. Blood pressure (BP) and heart rate were measured using a semiautomatic BP recording device with the participant in a supine position after at least 10 minutes of rest. Criteria for abnormalities included: Systolic BP (millimeters of mercury \[mmHg\]): value more than (\>) 150 and increase from baseline more than equal (\>= 30) or value less than (\<) 90 and decrease from baseline \>= 30; DBP: value \> 100 and increase from baseline \>=20 or Value \< 50 and decrease from baseline \>= 20; Heart Rate (beats per minute \[BPM\]): value \< 40 or \> 120.
Time frame: From start of study treatment until TOC visit (Up to Day 28)
Number of Participants With Abnormal Physical Examination Finding
A complete physical examination was performed and included an assessment of the following: general appearance including site of infection, skin, head and throat (head, eyes, ears, nose, and throat), lymph nodes, lungs, cardiovascular (CV), abdomen, musculoskeletal, and neurological systems.
Time frame: Screening, End of treatment (up to 24 hours post infusion on Day 14) and Test of Cure (Day 28)
Number of Participants With Abnormal Clinically Significant Electrocardiogram (ECG) Findings
Standard 12-lead ECGs were recorded with the participants in the supine position after the participant had rested in this position for 10 minutes. Clinically significant findings were based on investigators assessment.
Time frame: Baseline (latest non-missing value before start of treatment) and Day 3
Percentage of Participants With Clinical Cure at End of Treatment (EOT) Visit: ITT Analysis Set
Clinical cure was defined as improvement in baseline signs and symptoms such that after study treatment, no further antimicrobial treatment for the index infection (i.e., cIAI or HAP/VAP) was required. Additionally, for cIAI participants, no unplanned drainage or surgical intervention was necessary since the initial procedure. Clinical cure was determined by the Independent Clinical Adjudication Committee. 95% CI was based on Jeffrey's method.
Time frame: At EOT visit (Within 24 hours after last infusion on Day 14)
Percentage of Participants With Clinical Cure at EOT Visit: Micro-ITT Analysis Set
Clinical cure was defined as improvement in baseline signs and symptoms such that after study treatment, no further antimicrobial treatment for the index infection (i.e., cIAI or HAP/VAP) was required. For cIAI participants, no unplanned drainage or surgical intervention was necessary since the initial procedure. Clinical cure was determined by the Independent Clinical Adjudication Committee. 95% CI was based on Jeffrey's method.
Time frame: At EOT visit (Within 24 hours after last infusion on Day 14)
Percentage of Participants With Clinical Cure at EOT Visit: CE Analysis Set
Clinical cure = improvement in baseline signs and symptoms such that after study treatment, no further antimicrobial treatment for the index infection (i.e., cIAI or HAP/VAP) was required. Additionally, for cIAI participants, no unplanned drainage or surgical intervention was necessary since the initial procedure. Clinical cure was determined by the Independent Clinical Adjudication Committee. 95% CI was based on Jeffrey's method. CE analysis set: all participants in ITT analysis set; met criteria for cIAI, or HAP/VAP; received at least 48 hours of study treatment or \<48 hours of treatment before discontinuing study drug due to AE; no concomitant antibiotics for any baseline pathogens between first dose and TOC (except protocol-allowed antibiotics); no prior antibiotics other than allowed per protocol; no important protocol deviations; no clinical outcome of indeterminate at TOC; no monomicrobial infections due to non-eligible pathogens and did not have only Gram-positive pathogens.
Time frame: At EOT visit (Within 24 hours after last infusion on Day 14)
Percentage of Participants With Clinical Cure at EOT Visit: ME Analysis Set
Clinical cure was defined as improvement in baseline signs and symptoms such that after study treatment, no further antimicrobial treatment for the index infection (i.e., cIAI or HAP/VAP) was required. Additionally, for cIAI participants, no unplanned drainage or surgical intervention was necessary since the initial procedure. Clinical cure was determined by the Independent Clinical Adjudication Committee. 95% CI was based on Jeffrey's method.
Time frame: At EOT visit (Within 24 hours after last infusion on Day 14)
Percentage of Participants With Clinical Cure by Type of Infection at EOT Visit: ITT Analysis Set
Clinical cure was defined as improvement in baseline signs and symptoms such that after study treatment, no further antimicrobial treatment for the index infection (i.e., cIAI or HAP/VAP) was required. Additionally, for cIAI participants, no unplanned drainage or surgical intervention was necessary since the initial procedure. Clinical cure was determined by the Independent Clinical Adjudication Committee. 95% CI was based on Jeffrey's method.
Time frame: At EOT visit (Within 24 hours after last infusion on Day 14)
Percentage of Participants With Clinical Cure by Type of Infection at EOT Visit: CE Analysis Set
Clinical cure = improvement in baseline signs and symptoms such that after study treatment, no further antimicrobial treatment for the index infection (i.e., cIAI or HAP/VAP) was required. Additionally, for cIAI participants, no unplanned drainage or surgical intervention was necessary since the initial procedure. Clinical cure was determined by the Independent Clinical Adjudication Committee. 95% CI was based on Jeffrey's method. CE analysis set: all participants in ITT analysis set; met criteria for cIAI, or HAP/VAP; received at least 48 hours of study treatment or \<48 hours of treatment before discontinuing study drug due to AE; no concomitant antibiotics for any baseline pathogens between first dose and TOC (except protocol-allowed antibiotics); no prior antibiotics other than allowed per protocol; no important protocol deviations; no clinical outcome of indeterminate at TOC; no monomicrobial infections due to non-eligible pathogens and did not have only Gram-positive pathogens.
Time frame: At EOT visit (Within 24 hours after last infusion on Day 24)
Percentage of Participants With Clinical Cure by Pathogen Resistance Type at EOT Visit: Micro-ITT Analysis Set
Clinical cure was defined as improvement in baseline signs and symptoms such that after study treatment, no further antimicrobial treatment for the index infection (i.e., cIAI or HAP/VAP) was required. Additionally, for cIAI participants, no unplanned drainage or surgical intervention was necessary since the initial procedure. Clinical cure was determined by the Independent Clinical Adjudication Committee. Percentage of participants with clinical cure by pathogen resistance type (ATM non-susceptible and Meropenem non-susceptible based on European Committee on Antimicrobial Susceptibility Testing \[EUCAST\] criteria and Clinical and Laboratory Standards Institute \[CLSI\] criteria, Extended spectrum beta-lactamases \[ESBL\]-positive, Carbapenemase-positive, Serene Carbapenemase and Metallo-beta-lactamase-positive) is reported in this outcome measure.
Time frame: At EOT visit (Within 24 hours after last infusion on Day 14)
Percentage of Participants With Clinical Cure by Pathogen Resistance Type at TOC Visit: Micro-ITT Analysis Set
Clinical cure was defined as improvement in baseline signs and symptoms such that after study treatment, no further antimicrobial treatment for the index infection (i.e., cIAI or HAP/VAP) was required. Additionally, for cIAI participants, no unplanned drainage or surgical intervention was necessary since the initial procedure. Clinical cure was determined by the Independent Clinical Adjudication Committee. Percentage of participants with clinical cure by pathogen resistance type (ATM non-susceptible and Meropenem non-susceptible based on EUCAST criteria and CLSI criteria, ESBL-positive, Carbapenemase-positive, Serene Carbapenemase and Metallo-beta-lactamase-positive) is reported in this outcome measure.
Time frame: At TOC (Day 28)
Percentage of Participants With Clinical Cure by Pathogen Resistance Type at EOT Visit: ME Analysis Set
Clinical cure was defined as improvement in baseline signs and symptoms such that after study treatment, no further antimicrobial treatment for the index infection (i.e., cIAI or HAP/VAP) was required. Additionally, for cIAI participants, no unplanned drainage or surgical intervention was necessary since the initial procedure. Clinical cure was determined by the Independent Clinical Adjudication Committee. Percentage of participants with clinical cure by pathogen resistance type (ATM non-susceptible and Meropenem non-susceptible based on EUCAST criteria and CLSI criteria, ESBL-positive, Carbapenemase-positive, Serene Carbapenemase and Metallo-beta-lactamase-positive) is reported in this outcome measure.
Time frame: At EOT (Within 24 hours after last infusion on Day 14)
Percentage of Participants With Clinical Cure by Pathogen Resistance Type at TOC Visit: ME Analysis Set
Clinical cure was defined as improvement in baseline signs and symptoms such that after study treatment, no further antimicrobial treatment for the index infection (i.e., cIAI or HAP/VAP) was required. Additionally, for cIAI participants, no unplanned drainage or surgical intervention was necessary since the initial procedure. Clinical cure was determined by the Independent Clinical Adjudication Committee. Percentage of participants with clinical cure by pathogen resistance type (ATM non-susceptible and Meropenem non-susceptible based on EUCAST criteria and CLSI criteria, ESBL-positive, Carbapenemase-positive, Serene Carbapenemase and Metallo-beta-lactamase-positive) is reported in this outcome measure.
Time frame: At TOC visit (Day 28)
Percentage of Participants With Favorable Per Participant Microbiological Response at EOT Visit: Micro-ITT Analysis Set
Participants were determined to have a favorable microbiological response if all baseline pathogens for that participant had a favorable outcome (eradicated or presumed eradicated). Eradication: Absence of causative pathogen from an appropriately obtained specimen at the site of infection. Presumed eradication: repeat culture of specimens were not performed/clinically indicated in a participant who had a clinical response of cure.
Time frame: At EOT visit (Within 24 hours after last infusion on Day 14)
Percentage of Participants With Favorable Per Participant Microbiological Response at EOT Visit : ME Analysis Set
Participants were determined to have a favorable microbiological response if all baseline pathogens for that participant had a favorable outcome (eradicated or presumed eradicated). Eradication: Absence of causative pathogen from an appropriately obtained specimen at the site of infection. Presumed eradication: repeat culture of specimens were not performed/clinically indicated in a participant who had a clinical response of cure.
Time frame: At EOT visit (Within 24 hours after last infusion on Day 14)
Number of Participants With Favorable Microbiological Response Per-Pathogen at EOT Visit: Micro-ITT Analysis Set
Participants were determined to have a favorable microbiological response if all baseline pathogens for that participant had a favorable outcome (eradicated or presumed eradicated). Eradication: Absence of causative pathogen from an appropriately obtained specimen at the site of infection. Presumed eradication: repeat culture of specimens were not performed/clinically indicated in a participant who had a clinical response of cure. Only those pathogens are reported which had more than or equal to 10 isolates for either treatment group.
Time frame: At EOT (Within 24 hours after last infusion on Day 14)
Number of Participants With Favorable Microbiological Response Per-Pathogen at at TOC Visit: Micro-ITT Analysis Set
Participants were determined to have a favorable microbiological response if all baseline pathogens for that participant had a favorable outcome (eradicated or presumed eradicated). Eradication: Absence of causative pathogen from an appropriately obtained specimen at the site of infection. Presumed eradication: repeat culture of specimens were not performed/clinically indicated in a participant who had a clinical response of cure. Only those pathogens are reported which had more than or equal to 10 isolates for either treatment group.
Time frame: At TOC visit (Day 28)
Number of Participants With Favorable Microbiological Response Per-Pathogen at EOT Visit: ME Analysis Set
Participants were determined to have a favorable microbiological response if all baseline pathogens for that participant had a favorable outcome (eradicated or presumed eradicated). Eradication: Absence of causative pathogen from an appropriately obtained specimen at the site of infection. Presumed eradication: repeat culture of specimens were not performed/clinically indicated in a participant who had a clinical response of cure. Only those pathogens are reported which had more than or equal to 10 isolates for either treatment group.
Time frame: At EOT (Within 24 hours after last infusion on Day 14)
Number of Participants With Favorable Microbiological Response Per-Pathogen at TOC Visit: ME Analysis Set
Participants were determined to have a favorable microbiological response if all baseline pathogens for that participant had a favorable outcome (eradicated or presumed eradicated). Eradication: Absence of causative pathogen from an appropriately obtained specimen at the site of infection. Presumed eradication: repeat culture of specimens were not performed/clinically indicated in a participant who had a clinical response of cure. Only those pathogens are reported which had more than or equal to 10 isolates for either treatment group.
Time frame: At TOC visit (Day 28)
Percentage of Participants With Favorable Per-Participant Microbiological Response by Pathogen Resistance Type at EOT Visit: Micro-ITT Analysis Set
Participants were determined to have a favorable microbiological response if all baseline pathogens for that participant had a favorable outcome (eradicated or presumed eradicated). Eradication: Absence of causative pathogen from an appropriately obtained specimen at the site of infection. Presumed eradication: repeat culture of specimens were not performed/clinically indicated in a participant who had a clinical response of cure. Percentage of participants with favorable microbiological response by pathogen resistance type (ATM non-susceptible and Meropenem non-susceptible based on EUCAST criteria and CLSI criteria, ESBL-positive, Carbapenemase-positive, Serene Carbapenemase and Metallo-beta-lactamase-positive) is reported in this outcome measure.
Time frame: At EOT (Within 24 hours after last infusion on Day 14)
Percentage of Participants With Favorable Per-Participant Microbiological Response by Pathogen Resistance Type at TOC Visit: Micro-ITT Analysis Set
Participants were determined to have a favorable microbiological response if all baseline pathogens for that participant had a favorable outcome (eradicated or presumed eradicated). Eradication: Absence of causative pathogen from an appropriately obtained specimen at the site of infection. Presumed eradication: repeat culture of specimens were not performed/clinically indicated in a participant who had a clinical response of cure. Percentage of participants with favorable microbiological response by pathogen resistance type (ATM non-susceptible and Meropenem non-susceptible based on EUCAST criteria and CLSI criteria, ESBL-positive, Carbapenemase-positive, Serene Carbapenemase and Metallo-beta-lactamase-positive) is reported in this outcome measure.
Time frame: At TOC visit (Day 28)
Percentage of Participants With Favorable Per-Participant Microbiological Response by Pathogen Resistance Type at EOT Visit: ME Analysis Set
Participants were determined to have a favorable microbiological response if all baseline pathogens for that participant had a favorable outcome (eradicated or presumed eradicated). Eradication: Absence of causative pathogen from an appropriately obtained specimen at the site of infection. Presumed eradication: repeat culture of specimens were not performed/clinically indicated in a participant who had a clinical response of cure. Percentage of participants with favorable microbiological response by pathogen resistance type (ATM non-susceptible, Meropenem non-susceptible based on EUCAST criteria and CLSI criteria, ESBL-positive, Carbapenemase-positive, Serene Carbapenemase and Metallo-beta-lactamase-positive) is reported in this outcome measure.
Time frame: At EOT (Within 24 hours after last infusion on Day 14)
Percentage of Participants With Favorable Per-Participant Microbiological Response by Pathogen Resistance Type at TOC Visit: ME Analysis Set
Participants were determined to have a favorable microbiological response if all baseline pathogens for that participant had a favorable outcome (eradicated or presumed eradicated). Eradication: Absence of causative pathogen from an appropriately obtained specimen at the site of infection. Presumed eradication: repeat culture of specimens were not performed/clinically indicated in a participant who had a clinical response of cure. Percentage of participants with favorable microbiological response by pathogen resistance type (ATM non-susceptible, Meropenem non-susceptible based on EUCAST criteria and CLSI criteria, ESBL-positive, Carbapenemase-positive, Serene Carbapenemase and Metallo-beta-lactamase-positive) is reported in this outcome measure.
Time frame: At TOC visit (Day 28)
Percentage of Participants With Favorable Per-Pathogen Microbiological Response by Pathogen Resistance Type at EOT Visit: Micro-ITT Analysis Set
Participants were determined to have a favorable microbiological response if all baseline pathogens for that participant had a favorable outcome (eradicated or presumed eradicated). Eradication: Absence of causative pathogen from an appropriately obtained specimen at the site of infection. Presumed eradication: repeat culture of specimens were not performed/clinically indicated in a participant who had a clinical response of cure. Percentage of participants with favorable per-pathogen microbiological response by pathogen resistance type (ATM non-susceptible, Meropenem non-susceptible based on EUCAST criteria and CLSI criteria, ESBL-positive, Carbapenemase-positive, Serene Carbapenemase and Metallo-beta-lactamase-positive) is reported in this outcome measure.
Time frame: At EOT (Within 24 hours after last infusion on Day 14)
Percentage of Participants With Favorable Per-Pathogen Microbiological Response by Pathogen Resistance Type at TOC Visit: Micro-ITT Analysis Set
Participants were determined to have a favorable microbiological response if all baseline pathogens for that participant had a favorable outcome (eradicated or presumed eradicated). Eradication: Absence of causative pathogen from an appropriately obtained specimen at the site of infection. Presumed eradication: repeat culture of specimens were not performed/clinically indicated in a participant who had a clinical response of cure. Percentage of participants with favorable per-pathogen microbiological response by pathogen resistance type (ATM non-susceptible, Meropenem non-susceptible based on EUCAST criteria and CLSI criteria, ESBL-positive, Carbapenemase-positive, Serene Carbapenemase and Metallo-beta-lactamase-positive) is reported in this outcome measure.
Time frame: At TOC visit (Day 28)
Percentage of Participants With Favorable Per-Pathogen Microbiological Response by Pathogen Resistance Type at EOT Visit: ME Analysis Set
Participants were determined to have a favorable microbiological response if all baseline pathogens for that participant had a favorable outcome (eradicated or presumed eradicated). Eradication: Absence of causative pathogen from an appropriately obtained specimen at the site of infection. Presumed eradication: repeat culture of specimens were not performed/clinically indicated in a participant who had a clinical response of cure. Percentage of participants with favorable per-pathogen microbiological response by pathogen resistance type (ATM non-susceptible, Meropenem non-susceptible based on EUCAST criteria and CLSI criteria, ESBL-positive, Carbapenemase-positive, Serene Carbapenemase and Metallo-beta-lactamase-positive) is reported in this outcome measure.
Time frame: At EOT (Within 24 hours after last infusion on Day 14)
Percentage of Participants With Favorable Per-Pathogen Microbiological Response by Pathogen Resistance Type at TOC Visit: ME Analysis Set
Participants were determined to have a favorable microbiological response if all baseline pathogens for that participant had a favorable outcome (eradicated or presumed eradicated). Eradication: Absence of causative pathogen from an appropriately obtained specimen at the site of infection. Presumed eradication: repeat culture of specimens were not performed/clinically indicated in a participant who had a clinical response of cure. Percentage of participants with favorable per-pathogen microbiological response by pathogen resistance type (ATM non-susceptible, Meropenem non-susceptible based on EUCAST criteria and CLSI criteria, ESBL-positive, Carbapenemase-positive, Serene Carbapenemase and Metallo-beta-lactamase-positive) is reported in this outcome measure.
Time frame: At TOC visit (Day 28)
Number of Participants According to Total Score for the Composite Endpoint of Symptom-Based Objective Clinical Measures: ITT Analysis Set
Time frame: Up to Day 28
Number of Participants According to Total Score for the Composite Endpoint of Symptom-Based Objective Clinical Measures: CE Analysis Set
CE analysis set: all participants in ITT analysis set; met criteria for cIAI, or HAP/VAP; received at least 48 hours of study treatment or \<48 hours of treatment before discontinuing study drug due to AE; no concomitant antibiotics for any baseline pathogens between first dose and TOC (except protocol-allowed antibiotics); no prior antibiotics other than allowed per protocol; no important protocol deviations; no clinical outcome of indeterminate at TOC; no monomicrobial infections due to non-eligible pathogens and did not have only Gram-positive pathogens.
Time frame: Up to Day 28
Percentage of Participants Who Died on or Before 14 Days From Randomization: ITT Analysis Set
Percentage of participants who died on or before 14 days from randomization is reported in this outcome measure.
Time frame: From randomization up to 14 days
Total Length of Hospital Stay up to TOC Visit: ITT Analysis Set
The total length of hospital stay was defined as the total number of calendar days on which the participant was in the hospital from the date of randomization up to and including the specified time point of TOC.
Time frame: From randomization up to Day 28
Total Length of Hospital Stay up to TOC Visit: CE Analysis Set
The total length of hospital stay was defined as the total number of calendar days on which the participant was in the hospital from the date of randomization up to and including the specified time point of TOC. CE analysis set: all participants in ITT analysis set; met criteria for cIAI, or HAP/VAP; received at least 48 hours of study treatment or \<48 hours of treatment before discontinuing study drug due to AE; no concomitant antibiotics for any baseline pathogens between first dose and TOC (except protocol-allowed antibiotics); no prior antibiotics other than allowed per protocol; no important protocol deviations; no clinical outcome of indeterminate at TOC; no monomicrobial infections due to non-eligible pathogens and did not have only Gram-positive pathogens.
Time frame: From randomization up to Day 28
Duration of Study Treatment
The duration of therapy in calendar days were calculated as follows: Date of last dose of study drug - date of first dose of study drug +1.
Time frame: From first dose of study treatment until last dose of treatment (Up to 14 days)
Length of Intensive Care Unit (ICU) Stay: ITT Analysis Set
The total length of ICU stay was defined as the total number of calendar days on which the participant was in ICU for the period from date of randomization until the TOC visit.
Time frame: From randomization until TOC visit (Up to Day 28)
Length of Intensive Care Unit (ICU) Stay: CE Analysis Set
The total length of ICU stay was defined as the total number of calendar days on which the participant was in ICU for the period from date of randomization until the TOC visit. CE analysis set: all participants in ITT analysis set; met criteria for cIAI, or HAP/VAP; received at least 48 hours of study treatment or \<48 hours of treatment before discontinuing study drug due to AE; no concomitant antibiotics for any baseline pathogens between first dose and TOC (except protocol-allowed antibiotics); no prior antibiotics other than allowed per protocol; no important protocol deviations; no clinical outcome of indeterminate at TOC; no monomicrobial infections due to non-eligible pathogens and did not have only Gram-positive pathogens.
Time frame: From randomization until TOC visit (Up to Day 28)
Number of Participants Admitted to the ICU: ITT Analysis Set
Number of participants admitted to the ICU up to TOC were reported in this outcome measure.
Time frame: From randomization until TOC visit (Up to Day 28)
Number of Participants Admitted to the ICU: CE Analysis Set
The number of participants admitted to the ICU were reported in this outcome measure. CE analysis set: all participants in ITT analysis set; met criteria for cIAI, or HAP/VAP; received at least 48 hours of study treatment or \<48 hours of treatment before discontinuing study drug due to AE; no concomitant antibiotics for any baseline pathogens between first dose and TOC (except protocol-allowed antibiotics); no prior antibiotics other than allowed per protocol; no important protocol deviations; no clinical outcome of indeterminate at TOC; no monomicrobial infections due to non-eligible pathogens and did not have only Gram-positive pathogens.
Time frame: From randomization until TOC visit (Up to Day 28)
Number of Participants With Mechanical Ventilation: ITT Analysis Set
Number of participants with mechanical ventilation were reported in this outcome measure.
Time frame: From randomization until TOC visit (Up to Day 28)
Number of Participants With Mechanical Ventilation: CE Analysis Set
Number of participants with mechanical ventilation were reported in this outcome measure. CE analysis set: all participants in ITT analysis set; met criteria for cIAI, or HAP/VAP; received at least 48 hours of study treatment or \<48 hours of treatment before discontinuing study drug due to AE; no concomitant antibiotics for any baseline pathogens between first dose and TOC (except protocol-allowed antibiotics); no prior antibiotics other than allowed per protocol; no important protocol deviations; no clinical outcome of indeterminate at TOC; no monomicrobial infections due to non-eligible pathogens and did not have only Gram-positive pathogens.
Time frame: From randomization until TOC visit (Up to Day 28)
Duration of Mechanical Ventilation in HAP/VAP Participants: ITT Analysis Set
Duration of mechanical ventilation was defined as the total number of calendar days on which the participant required mechanical ventilation from the date of randomization up to TOC.
Time frame: From randomization until TOC visit (Up to Day 28)
Duration of Mechanical Ventilation in HAP/VAP Participants: CE Analysis Set
Duration of mechanical ventilation was defined as the total number of calendar days on which the participant required mechanical ventilation from the date of randomization up to TOC. CE analysis set: all participants in ITT analysis set; met criteria for cIAI, or HAP/VAP; received at least 48 hours of study treatment or \<48 hours of treatment before discontinuing study drug due to AE; no concomitant antibiotics for any baseline pathogens between first dose and TOC (except protocol-allowed antibiotics); no prior antibiotics other than allowed per protocol; no important protocol deviations; no clinical outcome of indeterminate at TOC; no monomicrobial infections due to non-eligible pathogens and did not have only Gram-positive pathogens.
Time frame: From randomization until TOC visit (Up to Day 28)
Number of Participants With Unplanned Surgical Interventions in Complicated Intra-abdominal Infections (cIAI) Participants: ITT Analysis Set
Unplanned surgical interventions was defined as those occurring after the initial qualifying surgical intervention and prior to the TOC visit. Number of cIAI participants with unplanned surgical intervention according to clinical response categories of cure and failure is reported in this outcome measure.
Time frame: From randomization until TOC visit (Up to Day 28)
Number of Participants With Unplanned Surgical Interventions in cIAI Participants: CE Analysis Set
Unplanned surgical interventions was defined as those occurring after the initial qualifying surgical intervention and prior to the TOC visit. Number of cIAI participants with unplanned surgical intervention according to clinical response categories of cure and failure is reported in this outcome measure.
Time frame: From randomization until TOC visit (Up to Day 28)
Participants who were hospitalized with a diagnosis of complicated intra-abdominal infection (cIAI) or nosocomial pneumonia (NP) including hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) were enrolled. This study was conducted across 20 countries from 05-Apr-2018 to 23-Feb-2023.
| Milestone | Aztreonam-avibactam ± Metronidazole | Meropenem± Colistimethate |
|---|---|---|
| Started | 282 | 140 |
| Participants with ciai | 208 | 104 |
| Participants with hap/vap | 74 | 36 |
| Completed | 242 | 122 |
| Not completed | 40 | 18 |
| Withdrew: Other | 2 | 2 |
| Withdrew: Withdrawal by subject | 16 | 3 |
| Withdrew: Physician decision | 1 | 0 |
| Withdrew: Death | 17 | 11 |
| Withdrew: Adverse event | 3 | 1 |
| Withdrew: Lost to follow-up | 1 | 1 |
Clinical cure was defined as improvement in baseline signs and symptoms such that after study treatment, no further antimicrobial treatment for the index infection (i.e., cIAI or HAP/VAP) was required. Additionally, for cIAI participants, no unplanned drainage or surgical intervention was necessary since the initial procedure. Clinical cure was determined by the Independent Clinical Adjudication Committee. 95% confidence interval (CI) was based on Jeffrey's method.
| Percentage of participants | Aztreonam-avibactam ± Metronidazole | Meropenem± Colistimethate |
|---|---|---|
| Percentage of Participants With Clinical Cure at Test of Cure (TOC) Visit: Intent-To-Treat (ITT) Analysis Set | 68.4 (62.8 to 73.7) | 65.7 (57.6 to 73.2) |
Clinical cure = improvement in baseline signs and symptoms such that after study treatment, no further antimicrobial treatment for the index infection (i.e., cIAI or HAP/VAP) was required. Additionally for cIAI participants, no unplanned drainage or surgical intervention was necessary since the initial procedure. Clinical cure was determined by Independent Clinical Adjudication Committee. 95% CI was based on Jeffrey's method. CE analysis set:all participants in ITT analysis set; met criteria for cIAI, or HAP/VAP; received at least 48 hours of study treatment or \<48 hours of treatment before discontinuing study drug due to AE; no concomitant antibiotics for any baseline pathogens between first dose and TOC (except protocol-allowed antibiotics); no prior antibiotics other than allowed per protocol; no important protocol deviations; no clinical outcome of indeterminate at TOC; no monomicrobial infections due to non-eligible pathogens and did not have only Gram-positive pathogens.
| Percentage of participants | Aztreonam-avibactam ± Metronidazole | Meropenem± Colistimethate |
|---|---|---|
| Percentage of Participants With Clinical Cure at TOC Visit: Clinically Evaluable (CE) Analysis Set | 77.0 (71.0 to 82.3) | 74.3 (65.3 to 81.9) |
Clinical cure was defined as improvement in baseline signs and symptoms such that after study treatment, no further antimicrobial treatment for the index infection (i.e., cIAI or HAP/VAP) was required. Additionally, for cIAI participants, no unplanned drainage or surgical intervention was necessary since the initial procedure. Clinical cure was determined by the Independent Clinical Adjudication Committee. 95% CI was based on Jeffrey's method.
| Percentage of participants | Aztreonam-avibactam ± Metronidazole | Meropenem± Colistimethate |
|---|---|---|
| Percentage of Participants With Clinical Cure at TOC Visit: Microbiological Intent-To-Treat (Micro-ITT) Analysis Set | 72.9 (66.0 to 79.0) | 72.3 (62.7 to 80.6) |
Clinical cure was defined as improvement in baseline signs and symptoms such that after study treatment, no further antimicrobial treatment for the index infection (i.e., cIAI or HAP/VAP) was required. Additionally, for cIAI participants, no unplanned drainage or surgical intervention was necessary since the initial procedure. Clinical cure was determined by the Independent Clinical Adjudication Committee. 95% CI was based on Jeffrey's method.
| Percentage of participants | Aztreonam-avibactam ± Metronidazole | Meropenem± Colistimethate |
|---|---|---|
| Percentage of Participants With Clinical Cure at TOC Visit: Microbiologically Evaluable (ME) Analysis Set | 78.5 (71.4 to 84.5) | 75.9 (65.7 to 84.3) |
Clinical cure was defined as improvement in baseline signs and symptoms such that after study treatment, no further antimicrobial treatment for the index infection (i.e., cIAI or HAP/VAP) was required. Additionally, for cIAI participants, no unplanned drainage or surgical intervention was necessary since the initial procedure. Clinical cure was determined by the Independent Clinical Adjudication Committee. 95% CI was based on Jeffrey's method.
| Percentage of participants | Aztreonam-avibactam ± Metronidazole | Meropenem± Colistimethate |
|---|---|---|
| cIAI | 76.4 (70.3 to 81.8) | 74.0 (65.0 to 81.7) |
| HAP/VAP | 45.9 (34.9 to 57.3) | 41.7 (26.7 to 57.9) |
Clinical cure = improvement in baseline signs and symptoms such that after study treatment, no further antimicrobial treatment for the index infection (i.e., cIAI or HAP/VAP) was required. Additionally, for cIAI participants, no unplanned drainage or surgical intervention was necessary since the initial procedure. Clinical cure was determined by the Independent Clinical Adjudication Committee. 95% CI was based on Jeffrey's method. CE analysis set:all participants in ITT analysis set; met criteria for cIAI, or HAP/VAP; received at least 48 hours of study treatment or \<48 hours of treatment before discontinuing study drug due to AE; no concomitant antibiotics for any baseline pathogens between first dose and TOC (except protocol-allowed antibiotics); no prior antibiotics other than allowed per protocol; no important protocol deviations; no clinical outcome of indeterminate at TOC; no monomicrobial infections due to non-eligible pathogens and did not have only Gram-positive pathogens.
| Percentage of participants | Aztreonam-avibactam ± Metronidazole | Meropenem± Colistimethate |
|---|---|---|
| cIAI | 85.1 (79.2 to 89.9) | 79.5 (69.9 to 87.1) |
| HAP/VAP | 46.7 (32.7 to 61.1) | 54.5 (34.3 to 73.7) |
Clinical cure was defined as improvement in baseline signs and symptoms such that after study treatment, no further antimicrobial treatment for the index infection (i.e., cIAI or HAP/VAP) was required. Additionally, for cIAI participants, no unplanned drainage or surgical intervention was necessary since the initial procedure. Clinical cure was determined by the Independent Clinical Adjudication Committee.
| Percentage of participants | Aztreonam-avibactam ± Metronidazole | Meropenem± Colistimethate |
|---|---|---|
| Percentage of Participants With Clinical Cure in Participants With Metallo-beta-lactamase (MBL) Positive Pathogen at TOC Visit: Micro-ITT Analysis Set | 28.6 | 66.7 |
Clinical cure was defined as improvement in baseline signs and symptoms such that after study treatment, no further antimicrobial treatment for the index infection (i.e., cIAI or HAP/VAP) was required. For cIAI participants, no unplanned drainage or surgical intervention was necessary since the initial procedure. Clinical cure was determined by the Independent Clinical Adjudication Committee.
| Percentage of participants | Aztreonam-avibactam ± Metronidazole | Meropenem± Colistimethate |
|---|---|---|
| Percentage of Participants With Clinical Cure in Participants With MBL Positive Pathogen at TOC Visit: ME Analysis Set | 50.0 | 0 |
Participants were determined to have a favorable microbiological response if all baseline pathogens for that participant had a favorable outcome (eradicated or presumed eradicated). Eradication: Absence of causative pathogen from an appropriately obtained specimen at the site of infection. Presumed eradication: repeat culture of specimens were not performed/clinically indicated in a participant who had a clinical response of cure.
| Percentage of participants | Aztreonam-avibactam ± Metronidazole | Meropenem± Colistimethate |
|---|---|---|
| Percentage of Participants With Favorable Per-Participant Microbiological Response at TOC Visit: Micro- ITT Analysis Set | 75.7 | 73.9 |
Participants were determined to have a favorable microbiological response if all baseline pathogens for that participant had a favorable outcome (eradicated or presumed eradicated). Eradication: Absence of causative pathogen from an appropriately obtained specimen at the site of infection. Presumed eradication: repeat culture of specimens were not performed/clinically indicated in a participant who had a clinical response of cure.
| Percentage of participants | Aztreonam-avibactam ± Metronidazole | Meropenem± Colistimethate |
|---|---|---|
| Percentage of Participants With Favorable Per-Participant Microbiological Response at TOC Visit: ME Analysis Set | 77.2 | 75.9 |
Percentage of participants who died on or before 28 days after randomization is reported in this outcome measure.
| Percentage of participants | Aztreonam-avibactam ± Metronidazole | Meropenem± Colistimethate |
|---|---|---|
| Percentage of Participants Who Died on or Before 28 Days After Randomization: ITT Analysis Set | 4.3 | 7.1 |
Percentage of participants who died on or before 28 days after randomization is reported in this outcome measure.
| Percenatge of participants | Aztreonam-avibactam ± Metronidazole | Meropenem± Colistimethate |
|---|---|---|
| Percentage of Participants Who Died on or Before 28 Days After Randomization: Micro-ITT Analysis Set | 2.8 | 6.4 |
Plasma concentration for aztreonam according to renal function (augmented, normal and mild, moderate and severe is presented in this outcome measure. Augmented = Creatinine clearance (CrCL) \> 150 milliliters per minute (mL/min); Normal \& Mild = CrCL \> 50 to \<=150 mL/min; Moderate = CrCL \> 30 to ≤ 50 mL/min; Severe = CrCL \> 15 to ≤ 30 mL/min.
| Milligram/Liter | Aztreonam-avibactam ± Metronidazole |
|---|---|
| Renal Function: Augmented:25 to 30 minutes post start of infusion on Day 1 | 43.3 ± 339.08 |
| Renal Function: Augmented:3.25 to 3.5 hours post start of infusion on Day 1 | 55.99 ± 287.36 |
| Renal Function: Augmented: 5.5 hours to 6.5 hours post loading infusion on Day 1 | 26.11 ± 338.5 |
| Renal Function: Normal & Mild: 25 to 30 min post start of infusion on Day 1 | 33.85 ± 234.46 |
| Renal Function: Normal & Mild:3.25 to 3.5 hours post start of infusion on Day 1 | 56.24 ± 222.32 |
| Renal Function: Normal & Mild:5.5 hours to 6.5 hours post start of infusion on Day 1 | 25.03 ± 115.83 |
| Renal Function: Normal & Mild:7.5 to 8.5 hours post start of infusion on Day 1 | 34.62 ± 54.42 |
| Renal Function: Moderate: 25 to 30 min post start of infusion on Day 1 | 54.49 ± 313.99 |
| Renal Function: Moderate: 3.25 to 3.5 hours post start of infusion on Day 1 | 73.72 ± 259.64 |
| Renal Function: Moderate: 5.5 hours to 6.5 hours post start of infusion on Day 1 | 52.45 ± 139.9 |
| Renal Function: Moderate: 7.5 to 8.5 hours post start of infusion on Day 1 | 34 ± NA |
| Renal Function: Severe: 25 to 30 min post start of infusion on Day 1 | 48.98 ± 187.86 |
| Renal Function: Severe: 3.25 to 3.5 hours post start of infusion on Day 1 | 50.31 ± 30.13 |
| Renal Function: Severe: 5.5 hours to 6.5 hours post start of infusion on Day 1 | 48.54 ± 46.87 |
| Renal Function: Severe: 7.5 to 8.5 hours post start of infusion on Day 1 | 29.42 ± 34.88 |
| Renal Function: Augmented: 2.75 to 3 hours post start of infusion on Day 4 | 46.11 ± 234.31 |
| Renal Function: Augmented: 3.5 to 4.5 hours post start of infusion on Day 4 | 33.56 ± 204.99 |
| Renal Function: Augmented: 5 to 6 hours post start of infusion on Day 4 | 19.56 ± 205.84 |
| Renal Function: Augmented: 7 to 8 hours post start of infusion on Day 4 | 14.1 ± NA |
| Renal Function: Normal & Mild: 2.75 to 3 hours post start of infusion on Day 4 | 56.59 ± 404.54 |
| Renal Function: Normal & Mild: 3.5 to 4.5 hours post start of infusion on Day 4 | 35.69 ± 422.52 |
| Renal Function: Normal & Mild: 5 to 6 hours post start of infusion on Day 4 | 21.75 ± 271.62 |
| Renal Function: Normal & Mild: 7 to 8 hours post start of infusion on Day 4 | 42.98 ± 62.54 |
| Renal Function: Moderate: 2.75 to 3 hours post start of infusion on Day 4 | 73.33 ± 183.2 |
| Renal Function: Moderate: 3.5 to 4.5 hours post start of infusion on Day 4 | 58 ± 129.36 |
| Renal Function: Moderate: 5 to 6 hours post start of infusion on Day 4 | 44.72 ± 59.15 |
| Renal Function: Moderate: 7 to 8 hours post start of infusion on Day 4 | 19.8 ± NA |
| Renal Function: Severe: 2.75 to 3 hours post start of infusion on Day 4 | 54.91 ± 45.17 |
| Renal Function: Severe: 3.5 to 4.5 hours post start of infusion on Day 4 | 45.17 ± 34.89 |
| Renal Function: Severe: 5 to 6 hours post start of infusion on Day 4 | 45.11 ± 57.13 |
| Renal Function: Severe:7 to 8 hours post start of infusion on Day 4 | 32.69 ± 55.56 |
Plasma concentration for avibactam according to renal function (augmented, normal and mild, moderate and severe is presented in this outcome measure. Augmented = CrCL \> 150 mL/min; Normal \& Mild = CrCL \> 50 to \<=150 mL/min; Moderate = CrCL \> 30 to ≤ 50 mL/min; Severe = CrCL \> 15 to ≤ 30 mL/min.
| Milligram/Liter | Aztreonam-avibactam ± Metronidazole |
|---|---|
| Renal Function: Augmented:25 to 30 minutes post start of infusion on Day 1 | 10.77 ± 353.86 |
| Renal Function: Augmented:3.25 to 3.5 hours post start of infusion on Day 1 | 12.6 ± 299.27 |
| Renal Function: Augmented: 5.5 hours to 6.5 hours post start of infusion on Day 1 | 4.75 ± 366.33 |
| Renal Function: Normal & Mild: 25 to 30 min post start of infusion on Day 1 | 8.81 ± 338.73 |
| Renal Function: Normal & Mild:3.25 to 3.5 hours post start of infusion on Day 1 | 13.76 ± 242.67 |
| Renal Function: Normal & Mild:5.5 hours to 6.5 hours post start of infusion on Day 1 | 4.85 ± 209.49 |
| Renal Function: Normal & Mild:7.5 to 8.5 hours post start of infusion on Day 1 | 7.18 ± 62.62 |
| Renal Function: Moderate: 25 to 30 min post start of infusion on Day 1 | 13.56 ± 383.79 |
| Renal Function: Moderate: 3.25 to 3.5 hours post start of infusion on Day 1 | 20.28 ± 262.6 |
| Renal Function: Moderate: 5.5 hours to 6.5 hours post start of infusion on Day 1 | 13.47 ± 160.75 |
| Renal Function: Moderate: 7.5 to 8.5 hours post start of infusion on Day 1 | 7.91 ± NA |
| Renal Function: Severe: 25 to 30 min post start of infusion on Day 1 | 14.11 ± 202.08 |
| Renal Function: Severe: 3.25 to 3.5 hours post start of infusion on Day 1 | 13.62 ± 39.68 |
| Renal Function: Severe: 5.5 hours to 6.5 hours post start of infusion on Day 1 | 11.6 ± 54.34 |
| Renal Function: Severe: 7.5 to 8.5 hours post start of infusion on Day 1 | 8 ± 57.91 |
| Renal Function: Augmented: 2.75 to 3 hours post start of infusion on Day 4 | 9.75 ± 289.96 |
| Renal Function: Augmented: 3.5 to 4.5 hours post start of infusion on Day 4 | 6.23 ± 263.94 |
| Renal Function: Augmented: 5 to 6 hours post start of infusion on Day 4 | 3.19 ± 265.65 |
| Renal Function: Augmented: 7 to 8 hours post start of infusion on Day 4 | 2.72 ± NA |
| Renal Function: Normal & Mild: 2.75 to 3 hours post start of infusion on Day 4 | 11.46 ± 504.77 |
| Renal Function: Normal & Mild: 3.5 to 4.5 hours post start of infusion on Day 4 | 6.29 ± 493.48 |
| Renal Function: Normal & Mild: 5 to 6 hours post start of infusion on Day 4 | 3.48 ± 382.3 |
| Renal Function: Normal & Mild: 7 to 8 hours post start of infusion on Day 4 | 6.19 ± 51.22 |
| Renal Function: Moderate: 2.75 to 3 hours post start of infusion on Day 4 | 16.98 ± 208.63 |
| Renal Function: Moderate: 3.5 to 4.5 hours post start of infusion on Day 4 | 12.86 ± 156.96 |
| Renal Function: Moderate: 5 to 6 hours post start of infusion on Day 4 | 9.23 ± 72.89 |
| Renal Function: Moderate: 7 to 8 hours post start of infusion on Day 4 | 4.35 ± NA |
| Renal Function: Severe: 2.75 to 3 hours post start of infusion on Day 4 | 14.35 ± 44.72 |
| Renal Function: Severe: 3.5 to 4.5 hours post start of infusion on Day 4 | 11.68 ± 42.15 |
| Renal Function: Severe: 5 to 6 hours post start of infusion on Day 4 | 9.99 ± 67.87 |
| Renal Function: Severe: Moderate: 7 to 8 hours post start of infusion on Day 4 | 8.97 ± 47.28 |
Population PK predicted maximum plasma concentration for a dosing interval at steady-state (Cmax,ss) for participants who received aztreonam-avibactam in studies C3601002 (NCT03329092) and C3601009 (NCT03580044). Clinical response categories included, clinical cure=improvement in baseline signs and symptoms such that after study treatment, no further antimicrobial treatment for the index infection (i.e., cIAI or HAP/VAP) was required. For cIAI participants, no unplanned drainage or surgical intervention was necessary since the initial procedure. Failure was defined as participants who met any of the following criteria like death (after receiving at least 48 hours of study treatment) and participants who received treatment with further antibiotics for the index infection. Indeterminate was defined as death (after receiving less than 48 hours of study treatment) and for cIAI participants inadequate infection source control at time of initial surgical procedure.
| Milligram per liter (mg/L) | Aztreonam- Avibactam |
|---|---|
| cIAI: Clinical cure | 52.47 ± 37.49 |
| cIAI: Failure | 56.71 ± 62.52 |
| cIAI: Indeterminate | 66.21 ± 12.7 |
| HAP:Clinical cure | 85.24 ± 48.49 |
| HAP: Failure | 64.57 ± 33.97 |
| HAP: Indeterminate | 61.79 ± 27.2 |
| VAP: Clinical Cure | 54.89 ± 30.42 |
| VAP: Failure | 56.5 ± 31.1 |
| VAP: Indeterminate | 85.34 ± NA |
Population PK predicted (%fT\>MIC ATM of 8 mg/L) for participants who received aztreonam-avibactam in studies C3601002 (NCT03329092) and C3601009 (NCT03580044). Clinical response categories included, clinical cure=improvement in baseline signs and symptoms such that after study treatment, no further antimicrobial treatment for the index infection (i.e., cIAI or HAP/VAP) was required. For cIAI participants, no unplanned drainage or surgical intervention was necessary since the initial procedure. Failure was defined as participants who met any of the following criteria like death (after receiving at least 48 hours of study treatment) and participants who received treatment with further antibiotics for the index infection. Indeterminate was defined as death (after receiving less than 48 hours of study treatment) and for cIAI participants inadequate infection source control at time of initial surgical procedure.
| Percentage of time | Aztreonam- Avibactam |
|---|---|
| cIAI: Clinical cure | 90.4 ± 41.9 |
| cIAI: Failure | 73.81 ± 134.39 |
| cIAI: Indeterminate | 100 ± 0 |
| HAP:Clinical cure | 97.87 ± 7.67 |
| HAP: Failure | 97.2 ± 8.4 |
| HAP: Indeterminate | 100 ± 0 |
| VAP: Clinical Cure | 95.29 ± 8.94 |
| VAP: Failure | 96.38 ± 10.02 |
| VAP: Indeterminate | 100 ± NA |
Population PK predicted (AUC24,ss) for participants who received aztreonam-avibactam in studies C3601002 (NCT03329092) and C3601009 (NCT03580044). Clinical response categories included, clinical cure=improvement in baseline signs and symptoms such that after study treatment, no further antimicrobial treatment for the index infection (i.e., cIAI or HAP/VAP) was required. For cIAI participants, no unplanned drainage or surgical intervention was necessary since the initial procedure. Failure was defined as participants who met any of the following criteria like death (after receiving at least 48 hours of study treatment) and participants who received treatment with further antibiotics for the index infection. Indeterminate was defined as death (after receiving less than 48 hours of study treatment) and for cIAI participants inadequate infection source control at time of initial surgical procedure.
| Milligram*hours per liter (mg*h/L) | Aztreonam- Avibactam |
|---|---|
| cIAI: Clinical cure | 816.18 ± 41.83 |
| cIAI: Failure | 877.5 ± 85.91 |
| cIAI: Indeterminate | 1069.1 ± 15.82 |
| HAP:Clinical cure | 1420.1 ± 54.62 |
| HAP: Failure | 1079.4 ± 34.1 |
| HAP: Indeterminate | 1056.8 ± 35.68 |
| VAP: Clinical cure | 858.39 ± 32.49 |
| VAP: Failure | 912.23 ± 38.1 |
| VAP: Indeterminate | 1084.6 ± NA |
Population PK predicted (Cmax,ss) for participants who received ATM-AVI in studies C3601002 (NCT03329092) and C3601009 (NCT03580044). Microbiological response included Favorable =baseline pathogens for participant had a favorable outcome. Eradication: Absence of causative pathogen from an appropriately obtained specimen at site of infection. Presumed eradication: repeat culture of specimens were not performed/clinically indicated in a participant who had a clinical response of cure. Unfavorable=persistence, persistence with increasing MIC, or presumed persistence. Persistence= Causative organism still present from appropriately obtained specimen at site of infection. Presumed persistence= Participant assessed as a clinical failure and repeat culture of specimens were not performed/clinically indicated. Indeterminate = death (after receiving \< 48 hours of study treatment) and for cIAI participants inadequate infection source control at time of initial surgical procedure.
| Milligram per liter (mg/L) | Aztreonam- Avibactam |
|---|---|
| cIAI: Favorable | 53.26 ± 34.03 |
| cIAI: Unfavorable | 53.71 ± 67.14 |
| cIAI: Indeterminate | 62.97 ± 9.49 |
| HAP:Favorable | 86.9 ± 71.56 |
| HAP: Unfavorable | 55.48 ± 38.83 |
| HAP: Indeterminate | 66.2 ± 33.87 |
| VAP: Favorable | 50.71 ± 37.56 |
| VAP: Unfavorable | 59.77 ± 31.52 |
| VAP: Indeterminate | 85.34 ± NA |
Population PK predicted (AUC24,ss) for participants who received ATM-AVI in studies C3601002 (NCT03329092) and C3601009 (NCT03580044). Microbiological response included Favorable =baseline pathogens for participant had a favorable outcome. Eradication: Absence of causative pathogen from an appropriately obtained specimen at site of infection. Presumed eradication: repeat culture of specimens were not performed/clinically indicated in a participant who had a clinical response of cure. Unfavorable=persistence, persistence with increasing MIC, or presumed persistence. Persistence= Causative organism still present from appropriately obtained specimen at site of infection. Presumed persistence= Participant assessed as a clinical failure and repeat culture of specimens were not performed/clinically indicated. Indeterminate = death (after receiving \< 48 hours of study treatment) and for cIAI participants inadequate infection source control at time of initial surgical procedure.
| Milligram*hours per liter | Aztreonam- Avibactam |
|---|---|
| cIAI: Favorable | 830.23 ± 38.42 |
| cIAI: Unfavorable | 826.63 ± 95.22 |
| cIAI: Indeterminate | 1010.2 ± 9.17 |
| HAP:Favorable | 1446.1 ± 82.6 |
| HAP: Unfavorable | 909.59 ± 45.06 |
| HAP: Indeterminate | 1237.9 ± 38.16 |
| VAP: Favorable | 760.26 ± 40.54 |
| VAP: Unfavorable | 974.21 ± 37.82 |
| VAP: Indeterminate | 1084.6 ± NA |
Population PK predicted (%fT\>MIC ATM of 8 mg/L) for participants who received ATM-AVI in studies C3601002 (NCT03329092) and C3601009 (NCT03580044). Microbiological response included Favorable =baseline pathogens for participant had a favorable outcome. Eradication: Absence of causative pathogen from an appropriately obtained specimen at site of infection. Presumed eradication: repeat culture of specimens were not performed/clinically indicated in a participant who had a clinical response of cure. Unfavorable=persistence, persistence with increasing MIC, or presumed persistence. Persistence= Causative organism still present from appropriately obtained specimen at site of infection. Presumed persistence= Participant assessed as a clinical failure and repeat culture of specimens were not performed/clinically indicated. Indeterminate = death (after receiving \< 48 hours of study treatment) and for cIAI participants inadequate infection source control at time of initial surgical procedure.
| Percentage of time | Aztreonam- Avibactam |
|---|---|
| cIAI: Favorable | 92.57 ± 17.66 |
| cIAI: Unfavorable | 68.02 ± 171.87 |
| cIAI: Indeterminate | 100 ± 0 |
| HAP:Favorable | 95.53 ± 11.05 |
| HAP: Unfavorable | 93.9 ± 14.14 |
| HAP: Indeterminate | 100 ± 0 |
| VAP: Favorable | 90.8 ± 12.3 |
| VAP: Unfavorable | 97.42 ± 9.54 |
| VAP: Indeterminate | 100 ± NA |
Population PK predicted (AUC24,ss) for participants who received aztreonam-avibactam in studies C3601002 (NCT03329092) and C3601009 (NCT03580044). Clinical response categories included, clinical cure=improvement in baseline signs and symptoms such that after study treatment, no further antimicrobial treatment for the index infection (i.e., cIAI or HAP/VAP) was required. For cIAI participants, no unplanned drainage or surgical intervention was necessary since the initial procedure. Failure was defined as participants who met any of the following criteria like death (after receiving at least 48 hours of study treatment) and participants who received treatment with further antibiotics for the index infection. Indeterminate was defined as death (after receiving less than 48 hours of study treatment) and for cIAI participants inadequate infection source control at time of initial surgical procedure.
| Milligram*hour per liter | Aztreonam- Avibactam |
|---|---|
| cIAI: Clinical cure | 164.92 ± 45.91 |
| cIAI: Failure | 187.41 ± 96.93 |
| cIAI: Indeterminate | 213.92 ± 20.81 |
| HAP:Clinical cure | 291.47 ± 61.75 |
| HAP: Failure | 214.99 ± 36.09 |
| HAP: Indeterminate | 257.37 ± 71.75 |
| VAP: Clinical cure | 176.95 ± 31.43 |
| VAP: Failure | 178.68 ± 38.99 |
| VAP: Indeterminate | 218.09 ± NA |
Population PK predicted (Cmax,ss) for participants who received aztreonam-avibactam in studies C3601002 (NCT03329092) and C3601009 (NCT03580044). Clinical response categories included, clinical cure=improvement in baseline signs and symptoms such that after study treatment, no further antimicrobial treatment for the index infection (i.e., cIAI or HAP/VAP) was required. For cIAI participants, no unplanned drainage or surgical intervention was necessary since the initial procedure. Failure was defined as participants who met any of the following criteria like death (after receiving at least 48 hours of study treatment) and participants who received treatment with further antibiotics for the index infection. Indeterminate was defined as death (after receiving less than 48 hours of study treatment) and for cIAI participants inadequate infection source control at time of initial surgical procedure.
| Milligram per liter (mg/L) | Aztreonam- Avibactam |
|---|---|
| cIAI: Clinical cure | 11.01 ± 42.14 |
| cIAI: Failure | 12.48 ± 72.59 |
| cIAI: Indeterminate | 14.04 ± 16.52 |
| HAP:Clinical cure | 18.41 ± 55.07 |
| HAP: Failure | 13.46 ± 33.52 |
| HAP: Indeterminate | 15.24 ± 49.1 |
| VAP: Clinical Cure | 11.64 ± 31.01 |
| VAP: Failure | 11.44 ± 32.65 |
| VAP: Indeterminate | 18.93 ± NA |
Population PK predicted (%fT\>CT of 2.5mg/L) for participants who received aztreonam-avibactam in studies C3601002 (NCT03329092) and C3601009 (NCT03580044). Clinical response categories included, clinical cure=improvement in baseline signs and symptoms such that after study treatment, no further antimicrobial treatment for the index infection (i.e., cIAI or HAP/VAP) was required. For cIAI participants, no unplanned drainage or surgical intervention was necessary since the initial procedure. Failure was defined as participants who met any of the following criteria like death (after receiving at least 48 hours of study treatment) and participants who received treatment with further antibiotics for the index infection. Indeterminate was defined as death (after receiving less than 48 hours of study treatment) and for cIAI participants inadequate infection source control at time of initial surgical procedure.
| Percentage of time | Aztreonam- Avibactam |
|---|---|
| cIAI: Clinical cure | 85.53 ± 43.26 |
| cIAI: Failure | 71.92 ± 133.68 |
| cIAI: Indeterminate | 98.52 ± 2.81 |
| HAP:Clinical cure | 95.99 ± 11.57 |
| HAP: Failure | 95.28 ± 12.12 |
| HAP: Indeterminate | 92.75 ± 11.19 |
| VAP: Clinical Cure | 92 ± 13.01 |
| VAP: Failure | 94.08 ± 12.93 |
| VAP: Indeterminate | 100 ± NA |
Population PK predicted (AUC24,ss) for participants who received ATM-AVI in studies C3601002 (NCT03329092) and C3601009 (NCT03580044). Microbiological response included Favorable =baseline pathogens for participant had a favorable outcome. Eradication: Absence of causative pathogen from an appropriately obtained specimen at site of infection. Presumed eradication: repeat culture of specimens were not performed/clinically indicated in a participant who had a clinical response of cure. Unfavorable=persistence, persistence with increasing MIC, or presumed persistence. Persistence= Causative organism still present from appropriately obtained specimen at site of infection. Presumed persistence= Participant assessed as a clinical failure and repeat culture of specimens were not performed/clinically indicated. Indeterminate = death (after receiving\<48 hours of study treatment) and for cIAI participants inadequate infection source control at time of initial surgical procedure.
| Milligram*hours per liter | Aztreonam- Avibactam |
|---|---|
| cIAI: Favorable | 166.4 ± 40.88 |
| cIAI: Unfavorable | 177.65 ± 106.25 |
| cIAI: Indeterminate | 197.01 ± 7.31 |
| HAP:Favorable | 293.49 ± 95.13 |
| HAP: Unfavorable | 196.38 ± 61.95 |
| HAP: Indeterminate | 359.31 ± 71.12 |
| VAP: Favorable | 157.79 ± 43.71 |
| VAP: Unfavorable | 192.85 ± 38.42 |
| VAP: Indeterminate | 218.09 ± NA |
Population PK predicted (Cmax,ss (mg/L)) for participants who received ATM-AVI in studies C3601002 (NCT03329092) and C3601009 (NCT03580044). Microbiological response included Favorable =baseline pathogens for participant had a favorable outcome. Eradication: Absence of causative pathogen from an appropriately obtained specimen at site of infection. Presumed eradication: repeat culture of specimens were not performed/clinically indicated in a participant who had a clinical response of cure. Unfavorable=persistence, persistence with increasing MIC, or presumed persistence. Persistence= Causative organism still present from appropriately obtained specimen at site of infection. Presumed persistence= Participant assessed as a clinical failure and repeat culture of specimens were not performed/clinically indicated. Indeterminate = death (after receiving\<48 hours of study treatment) and for cIAI participants inadequate infection source control at time of initial surgical procedure.
| Milligram per liter (mg/L) | Aztreonam- Avibactam |
|---|---|
| cIAI: Favorable | 11.1 ± 37.2 |
| cIAI: Unfavorable | 11.83 ± 76.48 |
| cIAI: Indeterminate | 13.03 ± 8.01 |
| HAP:Favorable | 18.55 ± 84.68 |
| HAP: Unfavorable | 12.31 ± 51.34 |
| HAP: Indeterminate | 18.72 ± 55.03 |
| VAP: Favorable | 10.75 ± 42.72 |
| VAP: Unfavorable | 12.28 ± 32.85 |
| VAP: Indeterminate | 18.93 ± NA |
Population PK predicted (%fT\>CT of 2.5 mg/L) for participants who received ATM-AVI in studies C3601002 (NCT03329092) and C3601009 (NCT03580044). Microbiological response included Favorable =baseline pathogens for participant had a favorable outcome. Eradication: Absence of causative pathogen from an appropriately obtained specimen at site of infection. Presumed eradication: repeat culture of specimens were not performed/clinically indicated in a participant who had a clinical response of cure. Unfavorable=persistence, persistence with increasing MIC, or presumed persistence. Persistence= Causative organism still present from appropriately obtained specimen at site of infection. Presumed persistence= Participant assessed as a clinical failure and repeat culture of specimens were not performed/clinically indicated. Indeterminate = death (after receiving \< 48 hours of study treatment) and for cIAI participants inadequate infection source control at time of initial surgical procedure.
| Percentage of time | Avibactam |
|---|---|
| cIAI: Favorable | 87.93 ± 21.78 |
| cIAI: Unfavorable | 66.43 ± 170.59 |
| cIAI: Indeterminate | 99.24 ± 1.52 |
| HAP:Favorable | 92.26 ± 16.44 |
| HAP: Unfavorable | 90.03 ± 18.83 |
| HAP: Indeterminate | 100 ± 0 |
| VAP: Favorable | 87.47 ± 16.8 |
| VAP: Unfavorable | 95.52 ± 11.79 |
| VAP: Indeterminate | 100 ± NA |
An adverse event (AE) was any untoward medical occurrence in a study participant administered medicinal product,; the event need not necessarily have a causal relationship with product treatment or usage. A serious adverse event (SAE) was any untoward medical occurrence at any dose that: resulted in death; was life-threatening; required inpatient hospitalization or prolongation of hospitalization; resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions); resulted in congenital abnormal/birth defect or considered an important medical event.
| Participants | Aztreonam-avibactam ± Metronidazole | Meropenem± Colistimethate |
|---|---|---|
| AEs | 177 | 87 |
| SAEs | 53 | 25 |
Criteria for potential clinically significant hematology results were as follows: hemoglobin, hematocrit and erythrocyte \<0.7\*lower limit of normal \[LLN\] and \>30% decrease from Baseline (DFB); \>1.3\*upper limit of normal (ULN) and \>30% increase from Baseline (IFB). Platelet count \<0.65\*LLN and \> 50% decrease from baseline; \> 1.5 \* ULN and \> 100% increase from baseline. leukocyte: \< 0.65\* LLN and \> 60% decrease from baseline; \> 1.5\* ULN and 100% increase from baseline. Neutrophils/leukocytes \< 0.65 \* LLN and \>75% decrease from baseline; \> 1.6\*ULN and \> 100% increase from baseline. Lymphocytes/leukocytes \< 0.25\* LLN and \> 75% decrease from baseline;\> 1.5\* ULN and \> 100% increase from baseline, Eosinophils/leukocytes, Monocytes/leukocytes, Basophils/leukocytes \> 4.0\* ULN and \> 300% increase from baseline.
| Participants | Aztreonam-avibactam ± Metronidazole | Meropenem± Colistimethate |
|---|---|---|
| Hematocrit < 0.7*LLN and > 30% Decrease from Baseline | 6 | 3 |
| Hematocrit > 1.3* ULN and > 30% Increase from Baseline | 0 | 0 |
| Hemoglobin< 0.7* LLN and > 30% Decrease from Baseline | 8 | 3 |
| Hemoglobin > 1.3* ULN and > 30% Increase from Baseline | 0 | 0 |
| Erythrocytes < 0.7* LLN and > 30% Decrease from Baseline | 7 | 3 |
| Erythrocytes > 1.3* ULN and > 30% Increase from Baseline | 0 | 0 |
| Leukocytes < 0.65* LLN and > 60% Decrease from Baseline | 0 | 0 |
| Leukocytes > 1.5* ULN and > 100% Increase from Baseline | 12 | 5 |
| Neutrophils/Leukocytes < 0.65* LLN and > 75% Decrease from Baseline | 0 | 0 |
| Neutrophils/Leukocytes > 1.6* ULN and > 100% Increase from Baseline | 0 | 0 |
| Monocytes/Leukocytes > 4.0* ULN and > 300% Increase from Baseline | 0 | 0 |
| Lymphocytes/Leukocytes < 0.25* LLN and > 75% Decrease from Baseline | 1 | 1 |
| Lymphocytes/Leukocytes > 1.5* ULN and > 100% Increase from Baseline | 0 | 0 |
| Eosinophils/Leukocytes > 4.0* ULN and > 300% Increase from Baseline | 0 | 0 |
| Basophils/Leukocytes > 4.0* ULN and > 300% Increase from Baseline | 0 | 0 |
| Platelets < 0.65* LLN and > 50% Decrease from Baseline | 3 | 2 |
| Platelets > 1.5* ULN and > 100% Increase from Baseline | 12 | 7 |
Albumin \< 0.5\* LLN and\> 50% decrease from baseline (DFB);\> 1.5 \* ULN and\> 50% increase from baseline (IFB). Alkaline phosphatase \< 0.5 \* LLN and\> 80% DFB;\> 3.0 \* ULN and\> 100%. Alanine and Aspartate aminotransferase \> 3.0 \* ULN and\> 100% IFB. Bicarbonate \< 0.7 \* LLN and \> 40% DFB;\> 1.3 \* ULN and\> 40% IFB. Blood urea nitrogen \< 0.2 \* LLN and \> 100% DFB; \> 3.0 \* ULN and \> 200% IFB. Calcium \< 0.7 \* LLN and \> 30% DFB;\> 1.3 \* ULN and\> 30% IFB. Chloride \< 0.8 \* LLN \>and 20% DFB; \> 1.2 \* ULN and \> 20% IFB. Creatinine \> 2.0 \* ULN and\> 100% IFB; Glucose \< 0.6 \* LLN and\> 40% DFB; \> 3.0 \* ULN and\> 200% IFB. Potassium \< 0.8 \* LLN and \> 20% DFB; \> 1.2 \* ULN and\> 20% IFB. Sodium \< 0.85 \* LLN and\> 10% DFB;\> 1.1 \* ULN and \>10% IFB. Bilirubin \> 1.5 \* ULN and \> 100% IFB.; Direct bilirubin \> 2.0 \* ULN and \> 150% IFB.
| Participants | Aztreonam-avibactam ± Metronidazole | Meropenem± Colistimethate |
|---|---|---|
| Aspartate Aminotransferase >3.0* ULN and > 100% Increase from Baseline | 25 | 14 |
| Alanine Aminotransferase > 3.0* ULN and > 100% Increase from Baseline | 24 | 10 |
| Alkaline Phosphatase < 0.5* LLN and > 80% Decrease from Baseline | 0 | 0 |
| Alkaline Phosphatase > 3.0* ULN and > 100% Increase from Baseline | 5 | 4 |
| Bilirubin > 1.5* ULN and > 100% Increase from Baseline | 2 | 3 |
| Direct Bilirubin > 2.0* ULN and > 150% Increase from Baseline | 2 | 0 |
| Creatinine > 2.0* ULN and > 100% Increase from Baseline | 0 | 3 |
| Sodium < 0.85* LLN and > 10% Decrease from Baseline | 0 | 0 |
| Sodium> 1.1* ULN and > 10% Increase from Baseline | 0 | 0 |
| Potassium < 0.8* LLN and > 20% Decrease from Baseline | 6 | 1 |
| Potassium > 1.2* ULN and > 20% Increase from Baseline | 5 | 4 |
| Chloride< 0.8* LLN and > 20% Decrease from Baseline | 0 | 0 |
| Chloride > 1.2* ULN and > 20% Increase from Baseline | 1 | 0 |
| Bicarbonate < 0.7* LLN and > 40% Decrease from Baseline | 0 | 0 |
| Bicarbonate > 1.3* ULN and > 40% Increase from Baseline | 3 | 1 |
| Calcium < 0.7* LLN and > 30% Decrease from Baseline | 2 | 1 |
| Calcium > 1.3* ULN and > 30% Increase from Baseline | 0 | 0 |
| Albumin < 0.5* LLN and > 50% Decrease from Baseline | 0 | 0 |
| Albumin > 1.5* ULN and > 50% Increase from Baseline | 0 | 0 |
| Glucose < 0.6* LLN and > 40% Decrease from Baseline | 0 | 1 |
| Glucose > 3.0* ULN and > 200% Increase from Baseline | 2 | 0 |
| Urea Nitrogen < 0.2* LLN and > 100% Decrease from Baseline | 0 | 0 |
| Urea Nitrogen > 3.0* ULN and > 200% Increase from Baseline | 0 | 0 |
Vitals signs, included blood pressure and, heart rate. Blood pressure (BP) and heart rate were measured using a semiautomatic BP recording device with the participant in a supine position after at least 10 minutes of rest. Criteria for abnormalities included: Systolic BP (millimeters of mercury \[mmHg\]): value more than (\>) 150 and increase from baseline more than equal (\>= 30) or value less than (\<) 90 and decrease from baseline \>= 30; DBP: value \> 100 and increase from baseline \>=20 or Value \< 50 and decrease from baseline \>= 20; Heart Rate (beats per minute \[BPM\]): value \< 40 or \> 120.
| Participants | Aztreonam-avibactam ± Metronidazole | Meropenem± Colistimethate |
|---|---|---|
| Systolic BP (mmHg) Value more than (>) 150 and increase from baseline more than equal (≥ to 30) | 35 | 16 |
| Systolic BP (mmHg) Value less than (<) 90 and decrease from baseline more than equal (≥) 30 | 8 | 3 |
| Diastolic BP (mmHg) Value > 100 and increase from baseline ≥ 20 | 8 | 0 |
| Diastolic BP (mmHg) Value < 50 and decrease from baseline ≥ 20 | 10 | 5 |
| Heart Rate (BPM) Value < 40 or > 120 | 265 | 135 |
A complete physical examination was performed and included an assessment of the following: general appearance including site of infection, skin, head and throat (head, eyes, ears, nose, and throat), lymph nodes, lungs, cardiovascular (CV), abdomen, musculoskeletal, and neurological systems.
| Participants | Aztreonam-avibactam ± Metronidazole | Meropenem± Colistimethate |
|---|---|---|
| Abdomen: Screening | 184 | 103 |
| Abdomen: End of Treatment | 56 | 30 |
| Abdomen: Test of Cure | 31 | 12 |
| Cardiovascular: Screening | 50 | 22 |
| Cardiovascular: End of Treatment | 27 | 14 |
| Cardiovascular: Test of Cure | 20 | 10 |
| Ears: Screening | 1 | 1 |
| Ears: End of Treatment | 0 | 1 |
| Ears:Test of Cure | 0 | 1 |
| Eyes: Screening | 13 | 4 |
| Eyes End of Treatment | 7 | 1 |
| Eyes: Test of Cure | 6 | 1 |
| General appearance: Screening | 77 | 35 |
| General appearance: End of Treatment | 34 | 15 |
| General appearance: Test of Cure | 16 | 8 |
| Head: Screening | 12 | 4 |
| Head: End of Treatment | 10 | 5 |
| Head: Test of Cure | 6 | 2 |
| Lungs: Screening | 70 | 37 |
| Lungs: End of Treatment | 45 | 15 |
| Lungs: Test of Cure | 22 | 8 |
| Lymph nodes: Screening | 1 | 0 |
| Lymph nodes: End of Treatment | 1 | 0 |
| Lymph nodes: Test of Cure | 0 | 0 |
| Musculoskeletal: Screening | 21 | 10 |
| Musculoskeletal: End of Treatment | 17 | 9 |
| Musculoskeletal: Test of Cure | 9 | 3 |
| Neurological: Screening | 37 | 13 |
| Neurological: End of Treatment | 34 | 9 |
| Neurological: Test of Cure | 17 | 6 |
| Nose: Screening | 4 | 3 |
| Nose: End of Treatment | 2 | 0 |
| Nose: Test of Cure | 1 | 0 |
| Skin: Screening | 47 | 25 |
| Skin: End of Treatment | 33 | 22 |
| Skin: Test of Cure | 21 | 12 |
| Throat: Screening | 9 | 0 |
| Throat: End of Treatment | 10 | 1 |
| Throat: Test of Cure | 4 | 1 |
Standard 12-lead ECGs were recorded with the participants in the supine position after the participant had rested in this position for 10 minutes. Clinically significant findings were based on investigators assessment.
| Participants | Aztreonam-avibactam ± Metronidazole | Meropenem± Colistimethate |
|---|---|---|
| Baseline | 16 | 5 |
| Day 3 | 11 | 6 |
Clinical cure was defined as improvement in baseline signs and symptoms such that after study treatment, no further antimicrobial treatment for the index infection (i.e., cIAI or HAP/VAP) was required. Additionally, for cIAI participants, no unplanned drainage or surgical intervention was necessary since the initial procedure. Clinical cure was determined by the Independent Clinical Adjudication Committee. 95% CI was based on Jeffrey's method.
| Percentage of participants | Aztreonam-avibactam ± Metronidazole | Meropenem± Colistimethate |
|---|---|---|
| Percentage of Participants With Clinical Cure at End of Treatment (EOT) Visit: ITT Analysis Set | 75.9 (70.6 to 80.6) | 73.6 (65.8 to 80.3) |
Clinical cure was defined as improvement in baseline signs and symptoms such that after study treatment, no further antimicrobial treatment for the index infection (i.e., cIAI or HAP/VAP) was required. For cIAI participants, no unplanned drainage or surgical intervention was necessary since the initial procedure. Clinical cure was determined by the Independent Clinical Adjudication Committee. 95% CI was based on Jeffrey's method.
| Percentage of participants | Aztreonam-avibactam ± Metronidazole | Meropenem± Colistimethate |
|---|---|---|
| Percentage of Participants With Clinical Cure at EOT Visit: Micro-ITT Analysis Set | 79.7 (73.3 to 85.1) | 80.9 (72.0 to 87.8) |
Clinical cure = improvement in baseline signs and symptoms such that after study treatment, no further antimicrobial treatment for the index infection (i.e., cIAI or HAP/VAP) was required. Additionally, for cIAI participants, no unplanned drainage or surgical intervention was necessary since the initial procedure. Clinical cure was determined by the Independent Clinical Adjudication Committee. 95% CI was based on Jeffrey's method. CE analysis set: all participants in ITT analysis set; met criteria for cIAI, or HAP/VAP; received at least 48 hours of study treatment or \<48 hours of treatment before discontinuing study drug due to AE; no concomitant antibiotics for any baseline pathogens between first dose and TOC (except protocol-allowed antibiotics); no prior antibiotics other than allowed per protocol; no important protocol deviations; no clinical outcome of indeterminate at TOC; no monomicrobial infections due to non-eligible pathogens and did not have only Gram-positive pathogens.
| Percentage of participants | Aztreonam-avibactam ± Metronidazole | Meropenem± Colistimethate |
|---|---|---|
| Percentage of Participants With Clinical Cure at EOT Visit: CE Analysis Set | 82.2 (76.6 to 86.8) | 81.9 (73.7 to 88.4) |
Clinical cure was defined as improvement in baseline signs and symptoms such that after study treatment, no further antimicrobial treatment for the index infection (i.e., cIAI or HAP/VAP) was required. Additionally, for cIAI participants, no unplanned drainage or surgical intervention was necessary since the initial procedure. Clinical cure was determined by the Independent Clinical Adjudication Committee. 95% CI was based on Jeffrey's method.
| Percentage of participants | Aztreonam-avibactam ± Metronidazole | Meropenem± Colistimethate |
|---|---|---|
| Percentage of Participants With Clinical Cure at EOT Visit: ME Analysis Set | 84.6 (78.1 to 89.7) | 83.5 (74.2 to 90.4) |
Clinical cure was defined as improvement in baseline signs and symptoms such that after study treatment, no further antimicrobial treatment for the index infection (i.e., cIAI or HAP/VAP) was required. Additionally, for cIAI participants, no unplanned drainage or surgical intervention was necessary since the initial procedure. Clinical cure was determined by the Independent Clinical Adjudication Committee. 95% CI was based on Jeffrey's method.
| Percentage of participants | Aztreonam-avibactam ± Metronidazole | Meropenem± Colistimethate |
|---|---|---|
| cIAI | 81.7 (76.1 to 86.5) | 79.8 (71.3 to 86.6) |
| HAP/VAP | 59.5 (48.1 to 70.1) | 55.6 (39.4 to 70.8) |
Clinical cure = improvement in baseline signs and symptoms such that after study treatment, no further antimicrobial treatment for the index infection (i.e., cIAI or HAP/VAP) was required. Additionally, for cIAI participants, no unplanned drainage or surgical intervention was necessary since the initial procedure. Clinical cure was determined by the Independent Clinical Adjudication Committee. 95% CI was based on Jeffrey's method. CE analysis set: all participants in ITT analysis set; met criteria for cIAI, or HAP/VAP; received at least 48 hours of study treatment or \<48 hours of treatment before discontinuing study drug due to AE; no concomitant antibiotics for any baseline pathogens between first dose and TOC (except protocol-allowed antibiotics); no prior antibiotics other than allowed per protocol; no important protocol deviations; no clinical outcome of indeterminate at TOC; no monomicrobial infections due to non-eligible pathogens and did not have only Gram-positive pathogens.
| Percentage of participants | Aztreonam-avibactam ± Metronidazole | Meropenem± Colistimethate |
|---|---|---|
| cIAI | 88.7 (83.2 to 92.8) | 85.5 (76.8 to 91.8) |
| HAP/VAP | 57.8 (43.2 to 71.4) | 68.2 (47.4 to 84.5) |
Clinical cure was defined as improvement in baseline signs and symptoms such that after study treatment, no further antimicrobial treatment for the index infection (i.e., cIAI or HAP/VAP) was required. Additionally, for cIAI participants, no unplanned drainage or surgical intervention was necessary since the initial procedure. Clinical cure was determined by the Independent Clinical Adjudication Committee. Percentage of participants with clinical cure by pathogen resistance type (ATM non-susceptible and Meropenem non-susceptible based on European Committee on Antimicrobial Susceptibility Testing \[EUCAST\] criteria and Clinical and Laboratory Standards Institute \[CLSI\] criteria, Extended spectrum beta-lactamases \[ESBL\]-positive, Carbapenemase-positive, Serene Carbapenemase and Metallo-beta-lactamase-positive) is reported in this outcome measure.
| Percentage of participants | Aztreonam-avibactam ± Metronidazole | Meropenem± Colistimethate |
|---|---|---|
| ATM non-susceptible, EUCAST | 74.5 | 75.0 |
| ATM non-susceptible, CLSI | 68.4 | 74.2 |
| Meropenem non-susceptible, EUCAST | 57.9 | 72.7 |
| Meropenem non-susceptible, CLSI | 58.8 | 75.0 |
| ESBL-positive | 72.0 | 75.0 |
| Carbapenemase-positive | 61.5 | 50.0 |
| Serene Carbapenemase | 57.1 | 33.3 |
| Metallo-beta-lactamase-positive | 57.1 | 66.7 |
Clinical cure was defined as improvement in baseline signs and symptoms such that after study treatment, no further antimicrobial treatment for the index infection (i.e., cIAI or HAP/VAP) was required. Additionally, for cIAI participants, no unplanned drainage or surgical intervention was necessary since the initial procedure. Clinical cure was determined by the Independent Clinical Adjudication Committee. Percentage of participants with clinical cure by pathogen resistance type (ATM non-susceptible and Meropenem non-susceptible based on EUCAST criteria and CLSI criteria, ESBL-positive, Carbapenemase-positive, Serene Carbapenemase and Metallo-beta-lactamase-positive) is reported in this outcome measure.
| Percentage of participants | Aztreonam-avibactam ± Metronidazole | Meropenem± Colistimethate |
|---|---|---|
| ATM non-susceptible, EUCAST | 63.6 | 55.6 |
| ATM non-susceptible, CLSI | 60.5 | 61.3 |
| Meropenem non-susceptible, | 42.1 | 45.5 |
| Meropenem non-susceptible, CLSI | 41.2 | 50.0 |
| ESBL-positive | 68.0 | 70.0 |
| Carbapenemase-positive | 30.8 | 33.3 |
| Serene Carbapenemase | 28.6 | 0 |
| Metallo-beta-lactamase-positive | 28.6 | 66.7 |
Clinical cure was defined as improvement in baseline signs and symptoms such that after study treatment, no further antimicrobial treatment for the index infection (i.e., cIAI or HAP/VAP) was required. Additionally, for cIAI participants, no unplanned drainage or surgical intervention was necessary since the initial procedure. Clinical cure was determined by the Independent Clinical Adjudication Committee. Percentage of participants with clinical cure by pathogen resistance type (ATM non-susceptible and Meropenem non-susceptible based on EUCAST criteria and CLSI criteria, ESBL-positive, Carbapenemase-positive, Serene Carbapenemase and Metallo-beta-lactamase-positive) is reported in this outcome measure.
| Percentage of participants | Aztreonam-avibactam ± Metronidazole | Meropenem± Colistimethate |
|---|---|---|
| ATM non-susceptible, EUCAST | 81.1 | 78.6 |
| ATM non-susceptible, CLSI | 76.7 | 76.0 |
| Meropenem non-susceptible, EUCAST | 69.2 | 62.5 |
| Meropenem non-susceptible, CLSI | 69.2 | 62.5 |
| ESBL-positive | 77.3 | 82.4 |
| Carbapenemase-positive | 80.0 | 25.0 |
| Serene Carbapenemase | 66.7 | 33.3 |
| Metallo-beta-lactamase-positive | 100.0 | 0 |
Clinical cure was defined as improvement in baseline signs and symptoms such that after study treatment, no further antimicrobial treatment for the index infection (i.e., cIAI or HAP/VAP) was required. Additionally, for cIAI participants, no unplanned drainage or surgical intervention was necessary since the initial procedure. Clinical cure was determined by the Independent Clinical Adjudication Committee. Percentage of participants with clinical cure by pathogen resistance type (ATM non-susceptible and Meropenem non-susceptible based on EUCAST criteria and CLSI criteria, ESBL-positive, Carbapenemase-positive, Serene Carbapenemase and Metallo-beta-lactamase-positive) is reported in this outcome measure.
| Percentage of participants | Aztreonam-avibactam ± Metronidazole | Meropenem± Colistimethate |
|---|---|---|
| ATM non-susceptible, EUCAST Criteria | 70.3 | 60.7 |
| ATM non-susceptible, CLSI Criteria | 66.7 | 64.0 |
| Meropenem non-susceptible, EUCAST Criteria | 46.2 | 37.5 |
| Meropenem non-susceptible, CLSI Criteria | 46.2 | 37.5 |
| ESBL-positive | 72.7 | 76.5 |
| Carbapenemase-positive | 40.0 | 0 |
| Serene Carbapenemase | 33.3 | 0 |
| Metallo-beta-lactamase-positive | 50.0 | 0 |
Participants were determined to have a favorable microbiological response if all baseline pathogens for that participant had a favorable outcome (eradicated or presumed eradicated). Eradication: Absence of causative pathogen from an appropriately obtained specimen at the site of infection. Presumed eradication: repeat culture of specimens were not performed/clinically indicated in a participant who had a clinical response of cure.
| Percentage of participants | Aztreonam-avibactam ± Metronidazole | Meropenem± Colistimethate |
|---|---|---|
| Percentage of Participants With Favorable Per Participant Microbiological Response at EOT Visit: Micro-ITT Analysis Set | 84.6 | 83.9 |
Participants were determined to have a favorable microbiological response if all baseline pathogens for that participant had a favorable outcome (eradicated or presumed eradicated). Eradication: Absence of causative pathogen from an appropriately obtained specimen at the site of infection. Presumed eradication: repeat culture of specimens were not performed/clinically indicated in a participant who had a clinical response of cure.
| Percentage of participants | Aztreonam-avibactam ± Metronidazole | Meropenem± Colistimethate |
|---|---|---|
| Percentage of Participants With Favorable Per Participant Microbiological Response at EOT Visit : ME Analysis Set | 85.9 | 86.1 |
Participants were determined to have a favorable microbiological response if all baseline pathogens for that participant had a favorable outcome (eradicated or presumed eradicated). Eradication: Absence of causative pathogen from an appropriately obtained specimen at the site of infection. Presumed eradication: repeat culture of specimens were not performed/clinically indicated in a participant who had a clinical response of cure. Only those pathogens are reported which had more than or equal to 10 isolates for either treatment group.
| Participants | Aztreonam-avibactam ± Metronidazole | Meropenem± Colistimethate |
|---|---|---|
| Escherichia coli | 95 | 48 |
| Klebsiella pneumoniae | 19 | 18 |
| Pseudomonas aeruginosa | 14 | 5 |
| Streptococcus anginosus group | 13 | 4 |
| Bacteroides fragilis | 13 | 7 |
| Bacteroides thetaiotaomicron | 8 | 1 |
Participants were determined to have a favorable microbiological response if all baseline pathogens for that participant had a favorable outcome (eradicated or presumed eradicated). Eradication: Absence of causative pathogen from an appropriately obtained specimen at the site of infection. Presumed eradication: repeat culture of specimens were not performed/clinically indicated in a participant who had a clinical response of cure. Only those pathogens are reported which had more than or equal to 10 isolates for either treatment group.
| Participants | Aztreonam-avibactam ± Metronidazole | Meropenem± Colistimethate |
|---|---|---|
| Escherichia coli | 91 | 44 |
| Klebsiella pneumoniae | 14 | 15 |
| Pseudomonas aeruginosa | 12 | 3 |
| Streptococcus anginosus group | 12 | 4 |
| Bacteroides fragilis | 14 | 7 |
| Bacteroides thetaiotaomicron | 8 | 1 |
Participants were determined to have a favorable microbiological response if all baseline pathogens for that participant had a favorable outcome (eradicated or presumed eradicated). Eradication: Absence of causative pathogen from an appropriately obtained specimen at the site of infection. Presumed eradication: repeat culture of specimens were not performed/clinically indicated in a participant who had a clinical response of cure. Only those pathogens are reported which had more than or equal to 10 isolates for either treatment group.
| Participants | Aztreonam-avibactam ± Metronidazole | Meropenem± Colistimethate |
|---|---|---|
| Escherichia coli | 90 | 44 |
| Klebsiella pneumoniae | 17 | 17 |
| Streptococcus anginosus group | 13 | 3 |
| Bacteroides fragilis | 13 | 6 |
| Bacteroides thetaiotaomicron | 8 | 1 |
Participants were determined to have a favorable microbiological response if all baseline pathogens for that participant had a favorable outcome (eradicated or presumed eradicated). Eradication: Absence of causative pathogen from an appropriately obtained specimen at the site of infection. Presumed eradication: repeat culture of specimens were not performed/clinically indicated in a participant who had a clinical response of cure. Only those pathogens are reported which had more than or equal to 10 isolates for either treatment group.
| Participants | Aztreonam-avibactam ± Metronidazole | Meropenem± Colistimethate |
|---|---|---|
| Escherichia coli | 86 | 40 |
| Klebsiella pneumoniae | 13 | 14 |
| Streptococcus anginosus group | 12 | 3 |
| Bacteroides fragilis | 14 | 6 |
| Bacteroides thetaiotaomicron | 8 | 1 |
Participants were determined to have a favorable microbiological response if all baseline pathogens for that participant had a favorable outcome (eradicated or presumed eradicated). Eradication: Absence of causative pathogen from an appropriately obtained specimen at the site of infection. Presumed eradication: repeat culture of specimens were not performed/clinically indicated in a participant who had a clinical response of cure. Percentage of participants with favorable microbiological response by pathogen resistance type (ATM non-susceptible and Meropenem non-susceptible based on EUCAST criteria and CLSI criteria, ESBL-positive, Carbapenemase-positive, Serene Carbapenemase and Metallo-beta-lactamase-positive) is reported in this outcome measure.
| Percentage of participants | Aztreonam-avibactam ± Metronidazole | Meropenem± Colistimethate |
|---|---|---|
| ATM non-susceptible: CLSI | 68.8 | 78.6 |
| ATM non-susceptible : EUCAST | 76.2 | 80.6 |
| Meropenem non-susceptible : CLSI | 57.1 | 66.7 |
| Meropenem non-susceptible : EUCAST | 57.1 | 66.7 |
| ESBL-positive | 78.3 | 84.2 |
| Carbapenamase-positive | 50.0 | 25.0 |
| Serene Carbapenamase-positive | 33.3 | 33.3 |
| Metallo-beta-lactamase-positive | 75.0 | 0.0 |
Participants were determined to have a favorable microbiological response if all baseline pathogens for that participant had a favorable outcome (eradicated or presumed eradicated). Eradication: Absence of causative pathogen from an appropriately obtained specimen at the site of infection. Presumed eradication: repeat culture of specimens were not performed/clinically indicated in a participant who had a clinical response of cure. Percentage of participants with favorable microbiological response by pathogen resistance type (ATM non-susceptible and Meropenem non-susceptible based on EUCAST criteria and CLSI criteria, ESBL-positive, Carbapenemase-positive, Serene Carbapenemase and Metallo-beta-lactamase-positive) is reported in this outcome measure.
| Percentage of participants | Aztreonam-avibactam ± Metronidazole | Meropenem± Colistimethate |
|---|---|---|
| ATM non-susceptible: CLSI | 59.4 | 59.3 |
| ATM non-susceptible: EUCAST | 66.7 | 60.0 |
| Meropenem non-susceptible: CLSI | 28.6 | 25.0 |
| Meropenem non-susceptible : EUCAST | 28.6 | 25.0 |
| ESBL-positive | 73.9 | 73.7 |
| Carbapenamase-positive | 20.0 | 0.0 |
| Serene Carbapenamase-positive | 16.7 | 0.0 |
| Metallo-beta-lactamase-positive | 25.0 | 0.0 |
Participants were determined to have a favorable microbiological response if all baseline pathogens for that participant had a favorable outcome (eradicated or presumed eradicated). Eradication: Absence of causative pathogen from an appropriately obtained specimen at the site of infection. Presumed eradication: repeat culture of specimens were not performed/clinically indicated in a participant who had a clinical response of cure. Percentage of participants with favorable microbiological response by pathogen resistance type (ATM non-susceptible, Meropenem non-susceptible based on EUCAST criteria and CLSI criteria, ESBL-positive, Carbapenemase-positive, Serene Carbapenemase and Metallo-beta-lactamase-positive) is reported in this outcome measure.
| Percentage of participants | Aztreonam-avibactam ± Metronidazole | Meropenem± Colistimethate |
|---|---|---|
| ATM non-susceptible: CLSI | 70.0 | 80.0 |
| ATM non-susceptible: EUCAST | 75.0 | 82.1 |
| Meropenem non-susceptible: CLSI | 53.8 | 62.5 |
| Meropenem non-susceptible: EUCAST | 53.8 | 62.5 |
| ESBL-positive | 77.3 | 88.2 |
| Carbapenamase-positive | 44.4 | 25.0 |
| Serene Carbapenamase-positive | 33.3 | 33.3 |
| Metallo-beta-lactamase-positive | 66.7 | 0.0 |
Participants were determined to have a favorable microbiological response if all baseline pathogens for that participant had a favorable outcome (eradicated or presumed eradicated). Eradication: Absence of causative pathogen from an appropriately obtained specimen at the site of infection. Presumed eradication: repeat culture of specimens were not performed/clinically indicated in a participant who had a clinical response of cure. Percentage of participants with favorable microbiological response by pathogen resistance type (ATM non-susceptible, Meropenem non-susceptible based on EUCAST criteria and CLSI criteria, ESBL-positive, Carbapenemase-positive, Serene Carbapenemase and Metallo-beta-lactamase-positive) is reported in this outcome measure.
| Percentage of participants | Aztreonam-avibactam ± Metronidazole | Meropenem± Colistimethate |
|---|---|---|
| ATM non-susceptible: CLSI | 60.0 | 60.0 |
| ATM non-susceptible: EUCAST | 66.7 | 60.7 |
| Meropenem non-susceptible: CLSI | 30.8 | 25.0 |
| Meropenem non-susceptible: EUCAST | 30.8 | 25.0 |
| ESBL-positive | 72.7 | 76.5 |
| Carbapenamase-positive | 22.2 | 0.0 |
| Serene Carbapenamase-positive | 16.7 | 0.0 |
| Metallo-beta-lactamase-positive | 33.3 | 0.0 |
Participants were determined to have a favorable microbiological response if all baseline pathogens for that participant had a favorable outcome (eradicated or presumed eradicated). Eradication: Absence of causative pathogen from an appropriately obtained specimen at the site of infection. Presumed eradication: repeat culture of specimens were not performed/clinically indicated in a participant who had a clinical response of cure. Percentage of participants with favorable per-pathogen microbiological response by pathogen resistance type (ATM non-susceptible, Meropenem non-susceptible based on EUCAST criteria and CLSI criteria, ESBL-positive, Carbapenemase-positive, Serene Carbapenemase and Metallo-beta-lactamase-positive) is reported in this outcome measure.
| Percentage of participants | Aztreonam-avibactam ± Metronidazole | Meropenem± Colistimethate |
|---|---|---|
| ATM non-susceptible: CLSI | 68.3 | 77.4 |
| ATM non-susceptible: EUCAST | 73.3 | 78.4 |
| Meropenem non-susceptible: CLSI | 60.0 | 75.0 |
| Meropenem non-susceptible : EUCAST | 59.1 | 72.7 |
| ESBL-positive | 72.0 | 80.0 |
| Carbapenemase-positive | 61.5 | 50.0 |
| Serine-carbapenemase-positive | 42.9 | 33.3 |
| Metallo-beta-lactamase-positive | 71.4 | 66.7 |
Participants were determined to have a favorable microbiological response if all baseline pathogens for that participant had a favorable outcome (eradicated or presumed eradicated). Eradication: Absence of causative pathogen from an appropriately obtained specimen at the site of infection. Presumed eradication: repeat culture of specimens were not performed/clinically indicated in a participant who had a clinical response of cure. Percentage of participants with favorable per-pathogen microbiological response by pathogen resistance type (ATM non-susceptible, Meropenem non-susceptible based on EUCAST criteria and CLSI criteria, ESBL-positive, Carbapenemase-positive, Serene Carbapenemase and Metallo-beta-lactamase-positive) is reported in this outcome measure.
| Percentage of participants | Aztreonam-avibactam ± Metronidazole | Meropenem± Colistimethate |
|---|---|---|
| ATM non-susceptible: CLSI | 58.5 | 58.1 |
| ATM non-susceptible: EUCAST | 63.3 | 56.8 |
| Meropenem non-susceptible: CLSI | 30.0 | 41.7 |
| Meropenem non-susceptible: EUCAST | 31.8 | 36.4 |
| ESBL-positive | 72.0 | 70.0 |
| Carbapenemase-positive | 23.1 | 33.3 |
| Serine-carbapenemase-positive | 14.3 | 0.0 |
| Metallo-beta-lactamase-positive | 28.6 | 66.7 |
Participants were determined to have a favorable microbiological response if all baseline pathogens for that participant had a favorable outcome (eradicated or presumed eradicated). Eradication: Absence of causative pathogen from an appropriately obtained specimen at the site of infection. Presumed eradication: repeat culture of specimens were not performed/clinically indicated in a participant who had a clinical response of cure. Percentage of participants with favorable per-pathogen microbiological response by pathogen resistance type (ATM non-susceptible, Meropenem non-susceptible based on EUCAST criteria and CLSI criteria, ESBL-positive, Carbapenemase-positive, Serene Carbapenemase and Metallo-beta-lactamase-positive) is reported in this outcome measure.
| Percentage of participants | Aztreonam-avibactam ± Metronidazole | Meropenem± Colistimethate |
|---|---|---|
| ATM non-susceptible: CLSI | 75.8 | 80.0 |
| ATM non-susceptible: EUCAST | 78.6 | 82.8 |
| Meropenem non-susceptible: CLSI | 62.5 | 62.5 |
| Meropenem non-susceptible: EUCAST | 62.5 | 62.5 |
| ESBL-positive | 77.3 | 88.2 |
| Carbapenemase-positive | 70.0 | 25.0 |
| Serine-carbapenemase-positive | 50. | 33.3 |
| Metallo-beta-lactamase-positive | 100.0 | 0.0 |
Participants were determined to have a favorable microbiological response if all baseline pathogens for that participant had a favorable outcome (eradicated or presumed eradicated). Eradication: Absence of causative pathogen from an appropriately obtained specimen at the site of infection. Presumed eradication: repeat culture of specimens were not performed/clinically indicated in a participant who had a clinical response of cure. Percentage of participants with favorable per-pathogen microbiological response by pathogen resistance type (ATM non-susceptible, Meropenem non-susceptible based on EUCAST criteria and CLSI criteria, ESBL-positive, Carbapenemase-positive, Serene Carbapenemase and Metallo-beta-lactamase-positive) is reported in this outcome measure.
| Percentage of participants | Aztreonam-avibactam ± Metronidazole | Meropenem± Colistimethate |
|---|---|---|
| ATM non-susceptible: CLSI | 63.6 | 60.0 |
| ATM non-susceptible: EUCAST | 66.7 | 62.1 |
| Meropenem non-susceptible: CLSI | 31.3 | 25.0 |
| Meropenem non-susceptible : EUCAST | 31.3 | 25.0 |
| ESBL-positive: | 77.3 | 76.5 |
| Carbapenemase-positive: | 30.0 | 0.0 |
| Serine-carbapenemase-positive | 16.7 | 0.0 |
| Metallo-beta-lactamase-positive: | 50.0 | 0.0 |
No measurements were reported for this outcome.
CE analysis set: all participants in ITT analysis set; met criteria for cIAI, or HAP/VAP; received at least 48 hours of study treatment or \<48 hours of treatment before discontinuing study drug due to AE; no concomitant antibiotics for any baseline pathogens between first dose and TOC (except protocol-allowed antibiotics); no prior antibiotics other than allowed per protocol; no important protocol deviations; no clinical outcome of indeterminate at TOC; no monomicrobial infections due to non-eligible pathogens and did not have only Gram-positive pathogens.
No measurements were reported for this outcome.
Percentage of participants who died on or before 14 days from randomization is reported in this outcome measure.
| Percentage of participants | Aztreonam-avibactam ± Metronidazole | Meropenem± Colistimethate |
|---|---|---|
| Percentage of Participants Who Died on or Before 14 Days From Randomization: ITT Analysis Set | 2.8 | 3.6 |
The total length of hospital stay was defined as the total number of calendar days on which the participant was in the hospital from the date of randomization up to and including the specified time point of TOC.
| Days | Aztreonam-avibactam ± Metronidazole | Meropenem± Colistimethate |
|---|---|---|
| Total Length of Hospital Stay up to TOC Visit: ITT Analysis Set | 13.6 ± 9.42 | 12.9 ± 8.05 |
The total length of hospital stay was defined as the total number of calendar days on which the participant was in the hospital from the date of randomization up to and including the specified time point of TOC. CE analysis set: all participants in ITT analysis set; met criteria for cIAI, or HAP/VAP; received at least 48 hours of study treatment or \<48 hours of treatment before discontinuing study drug due to AE; no concomitant antibiotics for any baseline pathogens between first dose and TOC (except protocol-allowed antibiotics); no prior antibiotics other than allowed per protocol; no important protocol deviations; no clinical outcome of indeterminate at TOC; no monomicrobial infections due to non-eligible pathogens and did not have only Gram-positive pathogens.
| Days | Aztreonam-avibactam ± Metronidazole | Meropenem± Colistimethate |
|---|---|---|
| Total Length of Hospital Stay up to TOC Visit: CE Analysis Set | 13.0 ± 8.55 | 12.3 ± 7.29 |
The duration of therapy in calendar days were calculated as follows: Date of last dose of study drug - date of first dose of study drug +1.
| Days | Aztreonam-avibactam ± Metronidazole | Meropenem± Colistimethate |
|---|---|---|
| Duration of Study Treatment | 8.5 ± 3.52 | 8.9 ± 3.17 |
The total length of ICU stay was defined as the total number of calendar days on which the participant was in ICU for the period from date of randomization until the TOC visit.
| Days | Aztreonam-avibactam ± Metronidazole | Meropenem± Colistimethate |
|---|---|---|
| Length of Intensive Care Unit (ICU) Stay: ITT Analysis Set | 11.6 ± 9.10 | 12.5 ± 9.45 |
The total length of ICU stay was defined as the total number of calendar days on which the participant was in ICU for the period from date of randomization until the TOC visit. CE analysis set: all participants in ITT analysis set; met criteria for cIAI, or HAP/VAP; received at least 48 hours of study treatment or \<48 hours of treatment before discontinuing study drug due to AE; no concomitant antibiotics for any baseline pathogens between first dose and TOC (except protocol-allowed antibiotics); no prior antibiotics other than allowed per protocol; no important protocol deviations; no clinical outcome of indeterminate at TOC; no monomicrobial infections due to non-eligible pathogens and did not have only Gram-positive pathogens.
| Days | Aztreonam-avibactam ± Metronidazole | Meropenem± Colistimethate |
|---|---|---|
| Length of Intensive Care Unit (ICU) Stay: CE Analysis Set | 12.1 ± 9.23 | 12.4 ± 9.38 |
Number of participants admitted to the ICU up to TOC were reported in this outcome measure.
| Participants | Aztreonam-avibactam ± Metronidazole | Meropenem± Colistimethate |
|---|---|---|
| Number of Participants Admitted to the ICU: ITT Analysis Set | 80 | 39 |
The number of participants admitted to the ICU were reported in this outcome measure. CE analysis set: all participants in ITT analysis set; met criteria for cIAI, or HAP/VAP; received at least 48 hours of study treatment or \<48 hours of treatment before discontinuing study drug due to AE; no concomitant antibiotics for any baseline pathogens between first dose and TOC (except protocol-allowed antibiotics); no prior antibiotics other than allowed per protocol; no important protocol deviations; no clinical outcome of indeterminate at TOC; no monomicrobial infections due to non-eligible pathogens and did not have only Gram-positive pathogens.
| Participants | Aztreonam-avibactam ± Metronidazole | Meropenem± Colistimethate |
|---|---|---|
| Number of Participants Admitted to the ICU: CE Analysis Set | 54 | 24 |
Number of participants with mechanical ventilation were reported in this outcome measure.
| Participants | Aztreonam-avibactam ± Metronidazole | Meropenem± Colistimethate |
|---|---|---|
| Number of Participants With Mechanical Ventilation: ITT Analysis Set | 43 | 21 |
Number of participants with mechanical ventilation were reported in this outcome measure. CE analysis set: all participants in ITT analysis set; met criteria for cIAI, or HAP/VAP; received at least 48 hours of study treatment or \<48 hours of treatment before discontinuing study drug due to AE; no concomitant antibiotics for any baseline pathogens between first dose and TOC (except protocol-allowed antibiotics); no prior antibiotics other than allowed per protocol; no important protocol deviations; no clinical outcome of indeterminate at TOC; no monomicrobial infections due to non-eligible pathogens and did not have only Gram-positive pathogens.
| Participants | Aztreonam-avibactam ± Metronidazole | Meropenem± Colistimethate |
|---|---|---|
| Number of Participants With Mechanical Ventilation: CE Analysis Set | 24 | 13 |
Duration of mechanical ventilation was defined as the total number of calendar days on which the participant required mechanical ventilation from the date of randomization up to TOC.
| Days | Aztreonam-avibactam ± Metronidazole | Meropenem± Colistimethate |
|---|---|---|
| Duration of Mechanical Ventilation in HAP/VAP Participants: ITT Analysis Set | 14.2 ± 9.94 | 16.7 ± 11.16 |
Duration of mechanical ventilation was defined as the total number of calendar days on which the participant required mechanical ventilation from the date of randomization up to TOC. CE analysis set: all participants in ITT analysis set; met criteria for cIAI, or HAP/VAP; received at least 48 hours of study treatment or \<48 hours of treatment before discontinuing study drug due to AE; no concomitant antibiotics for any baseline pathogens between first dose and TOC (except protocol-allowed antibiotics); no prior antibiotics other than allowed per protocol; no important protocol deviations; no clinical outcome of indeterminate at TOC; no monomicrobial infections due to non-eligible pathogens and did not have only Gram-positive pathogens.
| Days | Aztreonam-avibactam ± Metronidazole | Meropenem± Colistimethate |
|---|---|---|
| Duration of Mechanical Ventilation in HAP/VAP Participants: CE Analysis Set | 17.4 ± 8.99 | 19.5 ± 11.16 |
Unplanned surgical interventions was defined as those occurring after the initial qualifying surgical intervention and prior to the TOC visit. Number of cIAI participants with unplanned surgical intervention according to clinical response categories of cure and failure is reported in this outcome measure.
| Participants | Aztreonam-avibactam ± Metronidazole | Meropenem± Colistimethate |
|---|---|---|
| Cure | 1 | 1 |
| Failure | 5 | 10 |
Unplanned surgical interventions was defined as those occurring after the initial qualifying surgical intervention and prior to the TOC visit. Number of cIAI participants with unplanned surgical intervention according to clinical response categories of cure and failure is reported in this outcome measure.
| Participants | Aztreonam-avibactam ± Metronidazole | Meropenem± Colistimethate |
|---|---|---|
| Cure | 1 | 1 |
| Failure | 5 | 9 |
Collected over All-cause mortality: From signing of informed consent until end of late follow up visit (Day 45); non-SAEs and SAEs: From start of study treatment until end of late follow-up visit (Up to Day 45).. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Aztreonam-avibactam ± Metronidazole | 20/282 (7.1%) | 53/275 (19.3%) | 113/275 (41.1%) |
| Meropenem± Colistimethate | 11/140 (7.9%) | 25/137 (18.2%) | 45/137 (32.8%) |
| Event | Aztreonam-avibactam ± Metronidazole | Meropenem± Colistimethate |
|---|---|---|
| Septic shockInfections and infestations | 2/275 | 3/137 |
| Cardiac arrestCardiac disorders | 2/275 | 2/137 |
| Intra-abdominal fluid collectionGastrointestinal disorders | 0/275 | 2/137 |
| Abdominal abscessInfections and infestations | 4/275 | 2/137 |
| SepsisInfections and infestations | 2/275 | 2/137 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 3/275 | 2/137 |
| PneumoniaInfections and infestations | 4/275 | 1/137 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 4/275 | 0/137 |
| COVID-19Infections and infestations | 3/275 | 0/137 |
| Disseminated intravascular coagulationBlood and lymphatic system disorders | 0/275 | 1/137 |
| Event | Aztreonam-avibactam ± Metronidazole | Meropenem± Colistimethate |
|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 20/275 | 7/137 |
| Alanine aminotransferase increasedInvestigations | 18/275 | 7/137 |
| DiarrhoeaGastrointestinal disorders | 16/275 | 5/137 |
| HypokalaemiaMetabolism and nutrition disorders | 16/275 | 4/137 |
| Aspartate aminotransferase increasedInvestigations | 15/275 | 5/137 |
| PyrexiaGeneral disorders | 14/275 | 5/137 |
| Hepatic function abnormalHepatobiliary disorders | 11/275 | 3/137 |
| NauseaGastrointestinal disorders | 10/275 | 3/137 |
| VomitingGastrointestinal disorders | 10/275 | 2/137 |
| Abdominal painGastrointestinal disorders | 6/275 | 4/137 |
The Intent to Treat (ITT) analysis set included all randomized participants regardless of receipt of study drug. Participants were analyzed according to the treatment to which they were randomized.
| Age, Continuous(Years) | Aztreonam-avibactam ± Metronidazole | Meropenem± Colistimethate | Total |
|---|---|---|---|
| Mean | 55.2 ± 17.84 | 54.0 ± 16.30 | 54.8 ± 17.33 |
| Sex: Female, Male(Participants) | Aztreonam-avibactam ± Metronidazole | Meropenem± Colistimethate | Total |
|---|---|---|---|
| Female | 96 | 39 | 135 |
| Male | 186 | 101 | 287 |
| Ethnicity (NIH/OMB)(Participants) | Aztreonam-avibactam ± Metronidazole | Meropenem± Colistimethate | Total |
|---|---|---|---|
| Hispanic or Latino | 58 | 21 | 79 |
| Not Hispanic or Latino | 213 | 113 | 326 |
| Unknown or Not Reported | 11 | 6 | 17 |
| Race/Ethnicity, Customized(Participants) | Aztreonam-avibactam ± Metronidazole | Meropenem± Colistimethate | Total |
|---|---|---|---|
| White | 164 | 64 | 228 |
| Black or African American | 1 | 1 | 2 |
| Asian | 107 | 69 | 176 |
| American Indian or Alaska Native | 7 | 2 | 9 |
| Mixed | 2 | 1 | 3 |
| Other | 0 | 1 | 1 |
| Not reported | 1 | 2 | 3 |
Showing the first 100 of 157 sites across 21 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Apr 2018 to primary completion in Feb 2023, 58 months.
Results were first posted in May 2024, 1 year 2 months after primary completion.
Of 16 phase 3 interventional studies under Pneumonia, Ventilator-Associated, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 59. This study's 58 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pneumonia, Ventilator-Associated →